<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11858820</article-id><article-id pub-id-type="pmcid-ver">PMC11858820.1</article-id><article-id pub-id-type="pmcaid">11858820</article-id><article-id pub-id-type="pmcaiid">11858820</article-id><article-id pub-id-type="pmid">40006623</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020256</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00256</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Recent Advances in Studying In Vitro Drug Permeation Across Mucosal Membranes</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Song</surname><given-names initials="J">Juan</given-names></name><xref rid="af1-pharmaceutics-17-00256" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="Z">Zizhao</given-names></name><xref rid="af2-pharmaceutics-17-00256" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0003-5095-6318</contrib-id><name name-style="western"><surname>Xie</surname><given-names initials="L">Lingxiao</given-names></name><xref rid="af1-pharmaceutics-17-00256" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-17-00256" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shen</surname><given-names initials="J">Jie</given-names></name><xref rid="af2-pharmaceutics-17-00256" ref-type="aff">2</xref><xref rid="c1-pharmaceutics-17-00256" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Paix&#227;o</surname><given-names initials="P">Paulo</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00256"><label>1</label>Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA; <email>juan_song@uri.edu</email></aff><aff id="af2-pharmaceutics-17-00256"><label>2</label>Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA; <email>zi.xu@northeastern.edu</email></aff><author-notes><corresp id="c1-pharmaceutics-17-00256"><label>*</label>Correspondence: <email>lingxiao_xie@uri.edu</email> (L.X.); <email>jie.shen@northeastern.edu</email> (J.S.); Tel.: +1-617-373-5981 (J.S.)</corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">480918</issue-id><elocation-id>256</elocation-id><history><date date-type="received"><day>31</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>10</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>25</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-03 03:25:32.647"><day>03</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-17-00256.pdf"/><abstract><p>Transmucosal drug products, such as aerosols, films, semisolids, suppositories, and tablets, have been developed for the treatment of various human diseases and conditions. Transmucosal drug absorption is highly influenced by the biological structures of the mucosa and the physiological environment specific to the administration route (e.g., nasal, rectal, and vaginal). Over the last few decades, in vitro permeation testing (IVPT) using animal tissues or in vitro cell cultures have been utilized as a cost-effective and efficient tool for evaluating drug release and permeation behavior, assisting in formulation development and quality control of transmucosal drug delivery systems. This review summarizes the key mucosal permeation barriers associated with representative transmucosal administration routes, as well as considerations for IVPT method development. It highlights various IVPT methods, including vertical diffusion cell, flow-through diffusion cell, Ussing chamber, and transwell systems. Additionally, future perspectives are discussed, such as the use of optical methods to study in vitro drug permeation and the development of in vitro&#8211;in vivo correlation (IVIVC) for transmucosal drug development. The potential of IVPT as part of in vitro bioequivalence assessment strategies for locally acting transmucosal drug products is also highlighted.</p></abstract><kwd-group><kwd>mucosa</kwd><kwd>in vitro permeation</kwd><kwd>physiological environment</kwd><kwd>locally acting</kwd><kwd>biorelevant</kwd><kwd>in vitro characterization-based bioequivalence</kwd></kwd-group><funding-group><award-group><funding-source>Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS)</funding-source><award-id>1U01FD007656</award-id></award-group><funding-statement>This review was supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a grant (1U01FD007656). The contents are those of the author(s) and do not necessarily represent the official views of or endorsement by FDA/HHS or the U.S. government.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00256"><title>1. Introduction</title><p>Mucosal membranes are commonly targeted for therapeutic delivery, owing to their rich blood supply and lack of a keratinized stratum corneum, which enable enhanced drug permeability and more efficient absorption of therapeutics for both systemic and localized drug actions compared to the skin [<xref rid="B1-pharmaceutics-17-00256" ref-type="bibr">1</xref>]. Non-oral mucosal delivery routes (e.g., nasal, rectal, vaginal) offer significant advantages, such as bypassing first-pass metabolism and enzymatic degradation associated with oral drug delivery, enabling targeted delivery to the site of action, enhancing bioavailability, and reducing systemic side effects. These mucosal administration routes are particularly valuable for delivering proteins, hormones, and other therapeutics with poor oral bioavailability, as well as for diseases and conditions (e.g., bacterial vaginosis, ulcerative colitis) at the local sites of action [<xref rid="B2-pharmaceutics-17-00256" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-17-00256" ref-type="bibr">3</xref>].</p><p>The efficiency of transmucosal drug delivery is generally influenced by: (1) the biological structure and mucus composition of the mucosa, which vary across administration routes [<xref rid="B4-pharmaceutics-17-00256" ref-type="bibr">4</xref>]; (2) the physicochemical properties of the drug, which determine its primary transport pathway (e.g., paracellular vs. transcellular) through the mucosal tissues; and (3) dosage forms or delivery systems utilized, which affect drug release and permeation behavior. Currently, transmucosal drug products approved by the U.S. Food and Drug Administration (FDA) are available in a variety of dosage forms, such as aerosols, films, semisolids, sprays, and tablets. Since these are considered complex drug products, it is critical to understand the impact of critical material and formulation parameters on drug permeation across the mucosa to facilitate the development of both innovator and generic transmucosal drug products.</p><p>Over the last few decades, in vitro permeation testing (IVPT) has been widely employed to assist in the selection of new chemical entities, formulation development, and to ensure consistent product performance of transmucosal drug products. IVPT typically involves the utilization of human or animal tissues mounted in diffusion cells, offering a cost-effective and efficient means of evaluating drug permeation behavior across biological membranes. This approach is instrumental in supporting formulation development, bioequivalence assessments, and regulatory review and approvals, particularly for locally acting semisolid drugs. Recent advances in IVPT methodologies also include the use of cell models and 3D-bioprinted tissues.</p><p>This review highlights recent progress in IVPT methodologies for evaluating drug permeation across mucosal membranes, particularly for locally acting transmucosal drug products. It provides an overview of the physiological environment and main transmucosal permeation barriers across different transmucosal routes and highlights various in vitro permeation techniques. The review also identifies key challenges and future perspectives for enhancing IVPT approaches to support drug product development.</p></sec><sec id="sec2-pharmaceutics-17-00256"><title>2. Main Permeation Barriers of Representative Mucosal Membranes</title><p>Understanding the physiological environment and permeation barriers of mucosal membranes is essential for developing biorelevant in vitro methods to study drug permeation. <xref rid="pharmaceutics-17-00256-f001" ref-type="fig">Figure 1</xref> provides an overview of the main permeation barriers associated with different mucosal membranes, and <xref rid="pharmaceutics-17-00256-t001" ref-type="table">Table 1</xref> summarizes their physiological characteristics.</p><sec id="sec2dot1-pharmaceutics-17-00256"><title>2.1. Ocular Mucosa</title><p>Topical ocular drug delivery is a well-established approach for treating eye diseases affecting the eye surface and anterior chamber, such as inflammation and glaucoma. Drug absorption following topical ocular administration involves a complex process, including dilution in tear fluid (7&#8211;30 &#956;L), diffusion across the mucin layer, penetration through the multilayered cornea, and transfer into the aqueous humor to reach the target sites such as the iris-ciliary body. While some drug absorption may occur through the conjunctiva/sclera, corneal absorption remains the primary route, particularly for diseases affecting the eye surface and anterior chamber [<xref rid="B7-pharmaceutics-17-00256" ref-type="bibr">7</xref>]. However, short drug retention in the precorneal area due to the nasolacrimal drainage effect and the limited capacity (7&#8211;10 &#956;L) of the cul-de-sac [<xref rid="B17-pharmaceutics-17-00256" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-00256" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-17-00256" ref-type="bibr">19</xref>] may restrict ocular drug permeation and bioavailability.</p><p>The cornea, composed of epithelium, stroma, and endothelium, presents distinct drug permeation barriers: (1) Epithelium is lipophilic and composed of non-keratinized stratified squamous cells. Tight junctions, arranged in a &#8220;ribbon-like&#8221; structure, restrict paracellular diffusion, allowing better permeability for hydrophobic drugs while limiting hydrophilic drug transport [<xref rid="B20-pharmaceutics-17-00256" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-17-00256" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceutics-17-00256" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-17-00256" ref-type="bibr">23</xref>]; (2) Stroma composed of a lamellar arrangement of collagen fibrils, accounts for 90% of corneal thickness and is highly hydrated, posing a significant barrier to lipophilic drugs but facilitating hydrophilic drug diffusion; and (3) Endothelium consists of a monolayer of leaky junctions, allowing the passage of macromolecules between the aqueous humor and stroma, which maintaining corneal clarity [<xref rid="B24-pharmaceutics-17-00256" ref-type="bibr">24</xref>].</p><p>The mucin layer on corneal and conjunctival epithelia plays a protective role by restricting the penetration of foreign molecules and maintaining mucosal barrier integrity [<xref rid="B24-pharmaceutics-17-00256" ref-type="bibr">24</xref>]. For instance, the presence of membrane-bound mucins has been shown to prevent corneal penetration of rose Bengal, an anionic organic dye used clinically to evaluate epithelial damage in conditions such as dry eye syndrome [<xref rid="B5-pharmaceutics-17-00256" ref-type="bibr">5</xref>]. Although the gel-like mucin layer permits the diffusion of small molecules, its mesh size may restrict the transport of macromolecules and microbes. To prolong precorneal retention and enhance corneal penetration, mucoadhesive formulations are often designed to interact with the mucus layer, improving drug absorption and therapeutic effect [<xref rid="B7-pharmaceutics-17-00256" ref-type="bibr">7</xref>].</p><p>A comprehensive understanding of the barrier properties and drug transport pathways within the cornea is critical for designing biorelevant IVPT methods to evaluate drug permeation. Effective models should incorporate tear fluid dynamics, mucin interactions, and layer-specific permeability to accurately predict in vivo performance and support formulation optimization of ocular drug delivery systems.</p></sec><sec id="sec2dot2-pharmaceutics-17-00256"><title>2.2. Nasal Mucosa</title><p>The nasal mucosa is a promising target for drug delivery due to its high vascularization, large surface area, and non-invasive accessibility. Intranasal drug products are commonly used to treat localized conditions such as nasal allergies, sinusitis, and congestion, providing rapid symptom relief with minimal systemic adverse effects [<xref rid="B8-pharmaceutics-17-00256" ref-type="bibr">8</xref>]. Additionally, the olfactory region enables drug delivery into the central nervous system (CNS), making it an attractive pathway for neurological therapies [<xref rid="B25-pharmaceutics-17-00256" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00256" ref-type="bibr">26</xref>].</p><p>The nasal respiratory mucosa consists of epithelium, basement membrane, and lamina propria. The epithelium is primarily composed of pseudostratified columnar epithelial cells, goblet cells, and mucous and serous glands, interconnected by tight junctions that restrict paracellular diffusion of hydrophilic drugs [<xref rid="B27-pharmaceutics-17-00256" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-17-00256" ref-type="bibr">28</xref>]. The pseudostratified columnar epithelial cells are further categorized into mucus secreting, ciliated, non-ciliated and basal cells. Ciliated and non-ciliated cells, covered with non-motile microvilli, provide a large surface area for drug absorption, while basal cells serve as progenitors within the collagen-based basement membrane, which overlays the lamina propria [<xref rid="B26-pharmaceutics-17-00256" ref-type="bibr">26</xref>]. The nasal mucus layer, rich in mucin, may trap large molecular weight (MW) drugs (e.g., peptides and proteins) [<xref rid="B29-pharmaceutics-17-00256" ref-type="bibr">29</xref>]. Moreover, mucociliary clearance affects drug residence and absorption efficiency [<xref rid="B30-pharmaceutics-17-00256" ref-type="bibr">30</xref>]. Approximately 20&#8211;40 mL of mucus is secreted daily, covering extensive nasal mucosa surface area (160 cm<sup>2</sup>). This continuous mucus turnover can reduce drug residence time and potentially bioavailability [<xref rid="B31-pharmaceutics-17-00256" ref-type="bibr">31</xref>]. Interestingly, the olfactory region in humans and primates contains minimal ciliated epithelium, leading to reduced drug clearance and prolonged drug retention [<xref rid="B32-pharmaceutics-17-00256" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-00256" ref-type="bibr">33</xref>], which is advantages for CNS drug delivery.</p><p>In order to develop biorelevant IVPT models for nasal drug delivery, it is essential to accurately mimic the nasal environment. Key factors to consider include mucin-drug interactions, mucus flow dynamics, mucociliary clearance mechanisms, and epithelial barriers along with drug transport pathways.</p></sec><sec id="sec2dot3-pharmaceutics-17-00256"><title>2.3. Rectal Mucosa</title><p>The rectum, the terminal portion of the large intestine, offers an alternative administration route for drug delivery with both local and systemic applications. Structurally, a normal adult human rectum is about 12&#8211;15 cm long with a surface area of 200&#8211;400 cm<sup>2</sup> [<xref rid="B34-pharmaceutics-17-00256" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-17-00256" ref-type="bibr">35</xref>]. Unlike the small intestine, it lacks villi and microvilli, resulting in a limited absorptive surface area. The rectal epithelium consists of columnar cells and goblet cells that are responsible for secreting mucus, forming a 100 &#956;m-thick layer that acts as a protective barrier and may hinder drug permeation [<xref rid="B12-pharmaceutics-17-00256" ref-type="bibr">12</xref>,<xref rid="B36-pharmaceutics-17-00256" ref-type="bibr">36</xref>].</p><p>Drug absorption across the rectal epithelium occurs through transcellular and paracellular routes [<xref rid="B13-pharmaceutics-17-00256" ref-type="bibr">13</xref>,<xref rid="B37-pharmaceutics-17-00256" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-17-00256" ref-type="bibr">38</xref>]. However, several physiological factors affect drug permeation: (1) Low fluid volume (1&#8211;3 mL) limits drug dissolution, impacting drug absorption [<xref rid="B36-pharmaceutics-17-00256" ref-type="bibr">36</xref>,<xref rid="B39-pharmaceutics-17-00256" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-17-00256" ref-type="bibr">40</xref>]; (2) Neutral pH with low buffering capacity, which may be altered by administrated drugs, potentially causing irritant; and (3) Presence of stool increases the viscosity of the rectal fluid, which may limit drug dissolution and mobility in the viscous rectal fluid [<xref rid="B37-pharmaceutics-17-00256" ref-type="bibr">37</xref>,<xref rid="B39-pharmaceutics-17-00256" ref-type="bibr">39</xref>,<xref rid="B41-pharmaceutics-17-00256" ref-type="bibr">41</xref>]. Other factors such as rectal wall motility and formulation retention ability in the rectum also influence drug permeation and absorption [<xref rid="B37-pharmaceutics-17-00256" ref-type="bibr">37</xref>,<xref rid="B42-pharmaceutics-17-00256" ref-type="bibr">42</xref>]. For effective drug permeation and absorption through the rectal route, a drug or conjugate must strike a balance between lipophilicity (to cross the epithelial layer) and hydrophilicity (to ensure dissolution in the rectal fluid) [<xref rid="B28-pharmaceutics-17-00256" ref-type="bibr">28</xref>]. Most rectal drug candidates are small molecules with MW &lt; 500 g/mol and logP values ranging from 1.20 to 4.88.</p><p>To develop biorelevant IVPT models to assist in rectal drug development and quality control, it is essential to replicate the mucosal environment. Incorporating mucosal viscosity, and pH variability in IVPT systems may potentially improve predictive accuracy for in vivo performance, supporting formulation optimization and bioequivalence assessments.</p></sec><sec id="sec2dot4-pharmaceutics-17-00256"><title>2.4. Vaginal Mucosa</title><p>The vagina is a fibromuscular tube extending from the cervix to the vulva, measuring approximately 7&#8211;10 cm in length and 4 cm in width [<xref rid="B43-pharmaceutics-17-00256" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-17-00256" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-17-00256" ref-type="bibr">45</xref>]. It is composed of four distinct layers: (1) Non-keratinizing stratified squamous epithelium; (2) Lamina propria (or tunica), which is rich in collagen, elastin, vascular and lymphatic channels; (3) Muscle layer with smooth muscle fibers arranged in both circular and longitudinal directions; and (4) Areolar connective tissue interwoven with a vascular plexus [<xref rid="B34-pharmaceutics-17-00256" ref-type="bibr">34</xref>].</p><p>The vaginal epithelium consists of basal and parabasal layers, held together by tight junctions, desmosomes, and intermediate junctions [<xref rid="B46-pharmaceutics-17-00256" ref-type="bibr">46</xref>]. Drug absorption involves two key steps: dissolution in the vaginal fluid followed by permeation through the epithelium. Previous studies indicated that most drugs permeated through the vagina via passive diffusion [<xref rid="B47-pharmaceutics-17-00256" ref-type="bibr">47</xref>]. Vaginal fluid (~0.51 mL, pH 3.5 to 4.5), is composed of cervical mucus, glandular secretions, transudates, and endometrial fluids [<xref rid="B16-pharmaceutics-17-00256" ref-type="bibr">16</xref>,<xref rid="B48-pharmaceutics-17-00256" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-17-00256" ref-type="bibr">49</xref>]. This fluid forms a thin mucus layer that influences drug absorption, bioadhesion and permeation, which could reduce the overall drug efficacy and residence time at the target tissue [<xref rid="B48-pharmaceutics-17-00256" ref-type="bibr">48</xref>,<xref rid="B50-pharmaceutics-17-00256" ref-type="bibr">50</xref>]. The mucus barrier provides greater resistance to large or charged molecules, while small, uncharged molecules diffuse more readily [<xref rid="B51-pharmaceutics-17-00256" ref-type="bibr">51</xref>].</p><p>In order to assess the released drug mobility in the vaginal fluid and permeation mechanisms across the vaginal membrane, a biorelevant IVPT model should closely mimic the vaginal environment. Key considerations include the use of simulated vaginal fluid (to replicate the pH and mucosal composition) and biological membrane such as animal vaginal tissues, excised human vaginal tissues, or artificial vaginal membranes, to simulate permeation barriers.</p></sec></sec><sec id="sec3-pharmaceutics-17-00256"><title>3. Drug Permeation Mechanisms Across Mucosa</title><p>Mucoadhesion, drug dissolution, and epithelial penetration are critical steps for effective drug permeation and absorption through mucosal tissues. Drug dissolution and diffusion through the mucosal layer largely depend on the physiological environment (e.g., pH, volume, viscosity) of the mucosal tissues, the physicochemical properties (e.g., partition coefficient, MW) of the drug, and the formulation matrix and release kinetics. Mucus, composed of glycoprotein (mucin, MW: ~1&#8211;40 &#215; 10<sup>6</sup> kDa), lipids, salts, proteins, and carbohydrates, forms a hydrogel-like barrier that protects epithelial cells [<xref rid="B4-pharmaceutics-17-00256" ref-type="bibr">4</xref>,<xref rid="B52-pharmaceutics-17-00256" ref-type="bibr">52</xref>]. Mucin, primarily secreted by goblet cells, creates a mesh-like network that traps large molecules and restricts drug transport [<xref rid="B53-pharmaceutics-17-00256" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceutics-17-00256" ref-type="bibr">54</xref>]. Effective permeation requires the ability of a drug to diffuse through mucus, equilibrate laterally, and partition into underlying tissues, typically driven by a concentration gradient [<xref rid="B55-pharmaceutics-17-00256" ref-type="bibr">55</xref>]. Strategies to improve mucus penetration include the use of mucus-penetrating particles [<xref rid="B56-pharmaceutics-17-00256" ref-type="bibr">56</xref>] and proteolytic enzymes to degrade mucin [<xref rid="B57-pharmaceutics-17-00256" ref-type="bibr">57</xref>].</p><p>Drug penetration through epithelial tissues occurs via two main pathways: (1) Paracellular pathway which relies on passive diffusion through tight junctions and is primarily used by hydrophilic compounds (e.g., peptides). Molecules with radii greater than 15 &#197; have significant permeation limitations due to tight-junction selectivity. (2) Transcellular pathway is preferred by lipophilic drugs to diffuse across epithelial cell membranes [<xref rid="B4-pharmaceutics-17-00256" ref-type="bibr">4</xref>]. Transcellular transport mechanisms include passive diffusion, carrier-mediated transport (active or facilitated diffusion) and endocytosis. Drug molecules move through passive diffusion along a concentration or electrochemical gradient without requiring energy. Unlike carrier-mediated transport, this process is not saturable and exhibits low structural selectivity [<xref rid="B58-pharmaceutics-17-00256" ref-type="bibr">58</xref>]. Overall, drug lipophilicity, MW, ionization state, and dissolution rate strongly influence drug transport pathways and subsequent absorption. For instance, lipophilic molecules with MW less than 1 kDa are absorbed rapidly and efficiently via the transcellular pathway across the nasal mucosa [<xref rid="B8-pharmaceutics-17-00256" ref-type="bibr">8</xref>]. Similarly, lipid solubility (e.g., carbonic anhydrase inhibitor) correlates directly with ocular permeation rates [<xref rid="B59-pharmaceutics-17-00256" ref-type="bibr">59</xref>]. It has been reported that the acidic environment (pH 3.5&#8211;4.5) facilitates drug dissolution, however, the vaginal mucus may restrict permeation of ionized compounds [<xref rid="B60-pharmaceutics-17-00256" ref-type="bibr">60</xref>].</p></sec><sec id="sec4-pharmaceutics-17-00256"><title>4. IVPT Considerations and Systems</title><p>IVPT is a critical tool for assessing drug permeation using excised tissues or cell membranes applied in diffusion cells or Transwell systems. Since its first introduction in the mid-1970s, IVPT systems have undergone significant advancements [<xref rid="B61-pharmaceutics-17-00256" ref-type="bibr">61</xref>]. Commonly used IVPT systems include vertical diffusion cell (VDC) apparatus, flow-through cell (FTC) apparatus, and Ussing chamber systems. Either an infinite or finite dosing strategy is implemented depending upon the study objective, with permeation rates estimated once a steady state is reached. In recent years, Transwell systems using cell layers and 3D tissue models have been developed to evaluate in vitro permeation behavior in vitro under biorelevant conditions. The receptor media used for IVPT of representative mucosae were summarized in <xref rid="pharmaceutics-17-00256-t002" ref-type="table">Table 2</xref>.</p><sec id="sec4dot1-pharmaceutics-17-00256"><title>4.1. Tissue-Based Models</title><p>For tissue models, it is critical to validate tissue integrity and thickness before and after IVPT studies to ensure reliable data. The IVPT duration has been reported to be up to 24 h for cornea, vaginal, rectal mucosa and 8 h for nasal mucosa [<xref rid="B78-pharmaceutics-17-00256" ref-type="bibr">78</xref>,<xref rid="B88-pharmaceutics-17-00256" ref-type="bibr">88</xref>,<xref rid="B89-pharmaceutics-17-00256" ref-type="bibr">89</xref>,<xref rid="B90-pharmaceutics-17-00256" ref-type="bibr">90</xref>]. In addition, tissue surface temperature should be carefully monitored and controlled throughout testing. Maintaining sink conditions is important to prevent saturation effects, particularly for poorly water-soluble drugs. Tissue variability must also be addressed by using tissues from multiple donors and conducting tests with sufficient replicates to ensure statistical robustness. <xref rid="pharmaceutics-17-00256-t003" ref-type="table">Table 3</xref> summarizes the tissue models commonly used for transmucosal permeation studies.</p><sec id="sec4dot1dot1-pharmaceutics-17-00256"><title>4.1.1. VDC Apparatus</title><p>The VDC apparatus, originally developed by Franz [<xref rid="B61-pharmaceutics-17-00256" ref-type="bibr">61</xref>], is widely used to evaluate in vitro performance, including in vitro release test (IVRT) and IVPT for topical drug products. It consists of two compartments: a donor cell and a receptor cell, with the tissue membrane mounted between them as the permeation barrier (<xref rid="pharmaceutics-17-00256-f002" ref-type="fig">Figure 2</xref>A). A water jacket is used to maintain a constant test temperature (e.g., 37 &#176;C). A simulated body fluid or buffered solution is added to the receptor cell [<xref rid="B47-pharmaceutics-17-00256" ref-type="bibr">47</xref>,<xref rid="B83-pharmaceutics-17-00256" ref-type="bibr">83</xref>], while a test formulation is applied to the donor cell. Homogeneous mixing and proper hydrodynamics in the receptor cell are obtained using a magnetic stirring bar. The receptor cell features a sampling port for withdrawing aliquots at predefined time intervals, enabling time-course analysis and medium replacement to maintain sink conditions. Key parameters to be considered for IVPT using a VDC apparatus include: dosing amount, effective permeation area, receptor volume, and hydrodynamic conditions in the receptor cell [<xref rid="B109-pharmaceutics-17-00256" ref-type="bibr">109</xref>]. These parameters must be carefully selected and controlled to minimize IVPT data variability and ensure reproducible and reliable results. While the VDC system is simple to use, a potential limitation is the decreasing of diffusion gradient caused by the accumulation of the permeating drug in the receptor compartment [<xref rid="B88-pharmaceutics-17-00256" ref-type="bibr">88</xref>]. Strategies to maintain sink conditions such as replacing and replenishing receptor media at each sampling time point, as well as optimizing sampling intervals can help mitigate this issue.</p></sec><sec id="sec4dot1dot2-pharmaceutics-17-00256"><title>4.1.2. FTC Apparatus</title><p>The FTC system features a vertical arrangement similar to the VDC apparatus (<xref rid="pharmaceutics-17-00256-f002" ref-type="fig">Figure 2</xref>B), but includes input and output ports in the receptor cell to enable continuous fluid flow. This design better simulates in vivo conditions compared to the static VDC apparatus, as it effectively maintains sink conditions and mimics blood flow beneath biological membranes [<xref rid="B110-pharmaceutics-17-00256" ref-type="bibr">110</xref>]. Flow rate is a critical parameter that influences drug permeation rates in the FTC apparatus. Depending upon drug solubility, low flow rates may lead to drug saturation in the receptor fluid, thus violating sink conditions and reducing permeation rates for highly permeable drugs. Conversely, high flow rates may cause excessive dilution, potentially underestimating permeation rates for low-permeability drugs [<xref rid="B111-pharmaceutics-17-00256" ref-type="bibr">111</xref>]. The FTC system offers numerous advantages, including auto-sampling, easy maintenance of sink conditions, and simulation of physiological conditions such as blood flow beneath biological membranes [<xref rid="B110-pharmaceutics-17-00256" ref-type="bibr">110</xref>]. However, the pumped volume must significantly exceed the receptor&#8217;s volume to thoroughly wash the permeating substance. Therefore, the receptor chamber volume should be kept small to manage the effluent volume effectively [<xref rid="B88-pharmaceutics-17-00256" ref-type="bibr">88</xref>].</p></sec><sec id="sec4dot1dot3-pharmaceutics-17-00256"><title>4.1.3. Ussing Chamber System</title><p>The Ussing chamber system, introduced by Hans Ussing in the early 1950s [<xref rid="B112-pharmaceutics-17-00256" ref-type="bibr">112</xref>], allows precise control of temperature and oxygenation while simultaneously measuring electric parameters to monitor tissue viability during IVPT studies [<xref rid="B113-pharmaceutics-17-00256" ref-type="bibr">113</xref>]. The Ussing chamber system is classified into two main types: circulating chambers and continuously perfused chambers. The Ussing chamber system typically consists of two main functional components: a chamber unit that houses the biological tissue and maintains hydrostatic pressure to prevent tissue damage caused by bending [<xref rid="B114-pharmaceutics-17-00256" ref-type="bibr">114</xref>]; and an electrical circuit that measures current (I) and voltage (V) to calculate resistance (R) and more complex parameters such as impedance and capacitance [<xref rid="B115-pharmaceutics-17-00256" ref-type="bibr">115</xref>]. The circulating chamber features a U-shaped tubing system filled with carbogen gas (95% of O<sub>2</sub> and 5% of CO<sub>2</sub>) and N<sub>2</sub> to maintain constant stirring and ensure mucosal viability [<xref rid="B88-pharmaceutics-17-00256" ref-type="bibr">88</xref>]. Ussing chambers are available in vertical (<xref rid="pharmaceutics-17-00256-f002" ref-type="fig">Figure 2</xref>C) and horizontal configurations, tailored for specific experiments. Key parameters to be considered for the Ussing chamber system include temperature, gassing, electrical interferences (noise), and offset voltages [<xref rid="B115-pharmaceutics-17-00256" ref-type="bibr">115</xref>]. While the Ussing chamber system can support both native human or animal tissue and cell models [<xref rid="B113-pharmaceutics-17-00256" ref-type="bibr">113</xref>], the viscosity of semisolids or dissolved solutes may impair gaseous and nutrient exchange, affecting cell viability and data accuracy [<xref rid="B88-pharmaceutics-17-00256" ref-type="bibr">88</xref>].</p></sec></sec><sec id="sec4dot2-pharmaceutics-17-00256"><title>4.2. Cell-Based Models</title><p>Cell-based models utilizing immortalized human cells or primary cell cultures assess drug permeation behavior and biocompatibility [<xref rid="B116-pharmaceutics-17-00256" ref-type="bibr">116</xref>]. These cell-based models can reduce the reliance on animal tissues and address translational challenges while enabling reproducible and ethically accepted methods in early drug development. Transepithelial electrical resistance (TEER) measurements are used to monitor the integrity of tight junctions and mucosal barriers [<xref rid="B81-pharmaceutics-17-00256" ref-type="bibr">81</xref>]. However, simplified cell models may not fully replicate the complex tissue environment, which limits their capacity for formulation evaluation [<xref rid="B117-pharmaceutics-17-00256" ref-type="bibr">117</xref>].</p><sec id="sec4dot2dot1-pharmaceutics-17-00256"><title>4.2.1. Transwell System</title><p>The transwell system (<xref rid="pharmaceutics-17-00256-f002" ref-type="fig">Figure 2</xref>D), equipped with polycarbonate or polyester membrane inserts cultured with cells, has been used for drug permeation studies [<xref rid="B38-pharmaceutics-17-00256" ref-type="bibr">38</xref>,<xref rid="B81-pharmaceutics-17-00256" ref-type="bibr">81</xref>]. Cell monolayers, acting as permeation barriers, typically take several days to form after cell seeding, and TEER measurements ensure monolayer integrity. Inserts with intact cell monolayer layers are transferred to the receiving wells containing a receptor medium (e.g., simulated vaginal fluid) and a test formulation is added to the insert/donor chamber. Samples are collected from receiving wells at predetermined time points and replaced with fresh media. It is critical to monitor TEER during IVPT to ensure cell monolayer integrity throughout the study [<xref rid="B81-pharmaceutics-17-00256" ref-type="bibr">81</xref>]. <xref rid="pharmaceutics-17-00256-t004" ref-type="table">Table 4</xref> provides an overview of cell models reported for transmucosal IVPT using transwells. While transwell models reduce animal use and support mechanistic studies, experimental variability can arise due to culture conditions and poorly characterized lipid compositions [<xref rid="B118-pharmaceutics-17-00256" ref-type="bibr">118</xref>].</p></sec><sec id="sec4dot2dot2-pharmaceutics-17-00256"><title>4.2.2. Corneal Cell Models</title><p>Primary human corneal epithelium (HCE) cells are not ideal for large-scale permeation studies, since primary cells cease to grow after a few passages in culture. As a result, immortalized human corneal epithelium cell lines such as HCE-S and SV 40 HCE-T are typically preferred for such studies, as shown in <xref rid="pharmaceutics-17-00256-t004" ref-type="table">Table 4</xref> [<xref rid="B121-pharmaceutics-17-00256" ref-type="bibr">121</xref>,<xref rid="B134-pharmaceutics-17-00256" ref-type="bibr">134</xref>]. HCE-S cells [<xref rid="B119-pharmaceutics-17-00256" ref-type="bibr">119</xref>,<xref rid="B135-pharmaceutics-17-00256" ref-type="bibr">135</xref>] can be readily cultured in basic DMEM and serum-based media, offering a distinct advantage over existing corneal epithelial cell lines. Although SV 40 HCE-T has been widely applied for in vitro models of HCE cells, the genomic content of HCE-T cells appeared to be different from a normal healthy genome, and they also showed a significant number of heterogeneous cell populations based on an array-based comparative genomic hybridization analysis [<xref rid="B135-pharmaceutics-17-00256" ref-type="bibr">135</xref>]. On the other hand, tetracycline-responsive HPV 16-E6/E7-transduced HCE cell clones [<xref rid="B121-pharmaceutics-17-00256" ref-type="bibr">121</xref>] exhibited tightly controlled inducible proliferation, relatively normal differentiation of the corneal epithelium, and characteristic HCE morphology. More recently, a human organotypic cornea with typical corneal structures was developed, which contains a single layer of endothelial cells and a multilayered epithelium with flat superficial cells. However, the barrier functions of the human organotypic cornea still need to be thoroughly evaluated.</p></sec><sec id="sec4dot2dot3-pharmaceutics-17-00256"><title>4.2.3. Nasal Cell Models</title><p>Immortalized nasal cell lines have been shown to have high proliferation rates, greater reproducibility, and lower costs, and are easier to maintain in culture compared to primary cell cultures [<xref rid="B123-pharmaceutics-17-00256" ref-type="bibr">123</xref>,<xref rid="B136-pharmaceutics-17-00256" ref-type="bibr">136</xref>]. RPMI 2650 is the only cell line derived from human nasal tissue; however, it has several limitations: (1) it lacks tight-junction expression; (2) it does not differentiate into goblet or ciliated cells; and (3) it fails to reach confluence [<xref rid="B137-pharmaceutics-17-00256" ref-type="bibr">137</xref>,<xref rid="B138-pharmaceutics-17-00256" ref-type="bibr">138</xref>]. Although RPMI 2650 cells have been used in some permeation studies, results were highly dependent on culture conditions. It was reported that the air&#8211;liquid interface culture of RPMI2650 cells could be suitable for in vitro permeation studies across nasal mucosa [<xref rid="B71-pharmaceutics-17-00256" ref-type="bibr">71</xref>].</p></sec><sec id="sec4dot2dot4-pharmaceutics-17-00256"><title>4.2.4. Rectal Cell Model</title><p>The Caco-2 monolayer model has been the main model for studying drug permeation through the rectal membrane. For example, rectal delivery of polymeric nanoparticles containing an anti-HIV drug, dapivirine, was evaluated using Caco-2 monolayers. The retention of the drug within the Caco-2 cell monolayers and pig mucosa showed a similar trend for different nanoparticle formulations, indicating in vivo relevance [<xref rid="B81-pharmaceutics-17-00256" ref-type="bibr">81</xref>].</p></sec><sec id="sec4dot2dot5-pharmaceutics-17-00256"><title>4.2.5. Vaginal Cell Models</title><p>Ectocervical cells appear to be the most interesting in vitro model for studying vaginal drug permeability histologically. Human ectocervical epithelial (hECE) cells have been shown to maintain most of the phenotypic and biological features of the human cervicovaginal epithelium in vivo, including intercellular tight junctions and polarization of apical and basolateral surfaces. However, a significant lack of human ectocervical explants limits this model&#8217;s application. In contrast, several continuous human cervicovaginal cell lines, which are easier to maintain than primary cells, are more readily accessible. Cultured cervical cell lines such as CaSki, ECE16-1, and HT3 have been shown to have leaky epithelia based on both TEER and pyranine permeability studies, resembling the epithelia derived from human explants [<xref rid="B126-pharmaceutics-17-00256" ref-type="bibr">126</xref>,<xref rid="B139-pharmaceutics-17-00256" ref-type="bibr">139</xref>]. The commercially available EpiVaginal<sup>&#174;</sup> model composed of untransformed human vaginal ectocervical (VEC) epithelial cells and nonepithelial elements such as dendritic cells and fibroblasts, presenting unique organotypic characteristics, has been utilized for IVPT of various drugs [<xref rid="B123-pharmaceutics-17-00256" ref-type="bibr">123</xref>]. However, this model lacks a mucosal component and is expensive, which may limit its applicability. HVE<sup>&#174;</sup> is composed of A431 cells derived from a vulval epidermoid carcinoma cultivated on an inert polycarbonate filter at the air&#8211;liquid interface in a chemically defined medium. This model has been shown to be histologically similar to the in vivo vaginal mucosa and is used to screen and assess active ingredients or formulations for vaginal administration [<xref rid="B88-pharmaceutics-17-00256" ref-type="bibr">88</xref>].</p><p>It is critical to note that research involving human and animal tissues requires review and approval or exemption from an institutional review board (IRB). In the United States, IRB exemption is generally granted for research using unidentifiable human tissue samples from cadavers. However, this may differ across countries. Nevertheless, researchers must carefully review tissue sources and material transfer details with their IRB and complete the appropriate human research ethics training according to institutional and national requirements. Additionally, research involving cells must be reviewed and approval by an institutional biosafety committee (IBC) to ensure compliance with relevant biosafety guidelines and to protect public health and the environment. Adherence to both biosafety and human research ethics guidelines is essential for conducting responsible and ethical research.</p></sec></sec><sec id="sec4dot3-pharmaceutics-17-00256"><title>4.3. Data Analysis</title><p>Transmucosal diffusion is generally a passive process driven by a concentration gradient. Initially, drug molecules must be released from the formulation vehicle to reach the mucosal interface, after which they partition into the upper layers of the mucosal tissue. A key parameter influencing the permeation rate is the drug&#8217;s lipid&#8211;water partition coefficient.</p><p>For tissue-based models, the concentration gradient across the mucosa may not be linear at the start of IVPT. Over time, however, a steady state is achieved, at which point Fick&#8217;s first law of diffusion can be applied to describe drug transport across the mucosal barrier. Fick&#8217;s first law relates to the amount of solute (dosed drug, <italic toggle="yes">Q</italic>), membrane area (<italic toggle="yes">A</italic>), time period (<italic toggle="yes">T</italic>) regarding the concentration gradient (&#916;<italic toggle="yes">C<sub>s</sub></italic>), the diffusion coefficient of the mucosal membrane (D), and the transport path length (<italic toggle="yes">h</italic>) (Equation (1)). A steady-state flux, <italic toggle="yes">J<sub>ss</sub></italic>, can then be defined (Equation (2)). Higuchi suggested that flux is more appropriately expressed in terms of thermodynamic activity, rather than relying on a concentration approximation [<xref rid="B140-pharmaceutics-17-00256" ref-type="bibr">140</xref>]. The constant maximum flux occurs when the solute (drug) solubility reaches the maximum value (<italic toggle="yes">S<sub>s</sub></italic>) in the tissue (Equation (3)). The thermodynamic activity of the solute (dosed drug) is generally defined as the fractional solubility of the solute (drug) in the tissue (<italic toggle="yes">C<sub>s</sub></italic>/<italic toggle="yes">S<sub>s</sub></italic>), which can also be expressed in terms of the solute (drug) concentration in the vehicle (formulation, <italic toggle="yes">C<sub>v</sub></italic>) and the partition coefficient <italic toggle="yes">K</italic> (<italic toggle="yes">K</italic> = <italic toggle="yes">C<sub>s</sub></italic>/<italic toggle="yes">S<sub>s</sub></italic>, Equation (4)) [<xref rid="B141-pharmaceutics-17-00256" ref-type="bibr">141</xref>].</p><p>The in vitro permeation rate is typically calculated by plotting the cumulative amount of drug permeated per unit of surface area against the square root of time. The slope of the regression line (derived from the linear portion of the curve) represents the permeation rate [<xref rid="B38-pharmaceutics-17-00256" ref-type="bibr">38</xref>].<disp-formula id="FD1-pharmaceutics-17-00256"><label>(1)</label><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>Q</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi><mml:mi>T</mml:mi><mml:mo>&#916;</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#160;</mml:mo><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>Q</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mi>V</mml:mi><mml:mo>+</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mo stretchy="false">&#8721;</mml:mo><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow><mml:mo>)</mml:mo><mml:mo>&#8901;</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="FD2-pharmaceutics-17-00256"><label>(2)</label><mml:math id="mm2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>J</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mo>&#916;</mml:mo><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>&#916;</mml:mo><mml:mi>t</mml:mi><mml:mo>&#8901;</mml:mo><mml:mi>A</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="FD3-pharmaceutics-17-00256"><label>(3)</label><mml:math id="mm3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>J</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi>D</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="FD4-pharmaceutics-17-00256"><label>(4)</label><mml:math id="mm4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>J</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi>K</mml:mi><mml:mi>D</mml:mi><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula>
where, <italic toggle="yes">C<sub>n</sub></italic> is the drug concentration at the respective time point, <italic toggle="yes">C<sub>n</sub></italic><sub>&#8722;1</sub> is the drug concentration at the previous time point, <italic toggle="yes">V</italic> is the medium volume in the receptor cell, <italic toggle="yes">V<sub>r</sub></italic> is the sampling volume, and <italic toggle="yes">A</italic> is the permeation area. &#916;<italic toggle="yes">Q<sub>t</sub></italic> is the difference in the drug amount permeated between two time points (&#916;<italic toggle="yes">t</italic>), and <italic toggle="yes">C</italic><sub>0</sub> is the initial drug concentration in the donor chamber.</p><p>Beyond the steady state, a transient model can be used to describe time-dependent drug permeation. Fick&#8217;s second law is used as a basic model for this, assuming that the tissue membrane is a pseudo-homogeneous membrane and that both drug partition coefficient and diffusion coefficient remain constant over time (Equation (5)). Various modeling approaches, including compartmental and complex models, have been developed to account for these dynamics [<xref rid="B141-pharmaceutics-17-00256" ref-type="bibr">141</xref>,<xref rid="B142-pharmaceutics-17-00256" ref-type="bibr">142</xref>].<disp-formula id="FD5-pharmaceutics-17-00256"><label>(5)</label><mml:math id="mm5" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mo>&#8706;</mml:mo><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>&#8706;</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>=</mml:mo><mml:mi>D</mml:mi><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mo>&#8706;</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>&#8706;</mml:mo><mml:msup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula>
where, <italic toggle="yes">C</italic> is the concentration of the permeating solute (drug) at time t and depth <italic toggle="yes">x</italic> within the tissue membrane.</p><p>For cell-based models, the apparent permeability coefficient (<italic toggle="yes">P<sub>app</sub></italic>) is calculated using the following equation:<disp-formula id="FD6-pharmaceutics-17-00256"><label>(6)</label><mml:math id="mm6" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>p</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>&#160;</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mo>&#183;</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>C</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula>
where <italic toggle="yes">Q</italic> is the total amount of drug permeated into the receptor compartment (&#956;g), <italic toggle="yes">A</italic> is the diffusion area (cm<sup>2</sup>), <italic toggle="yes">C</italic> is the initial drug concentration in the donor compartment (&#956;g/cm<sup>3</sup>), and <italic toggle="yes">t</italic> is the total duration of IVPT [<xref rid="B38-pharmaceutics-17-00256" ref-type="bibr">38</xref>].</p></sec></sec><sec id="sec5-pharmaceutics-17-00256"><title>5. Future Perspectives</title><p>IVPT has long been instrumental in studying transmucosal permeation mechanisms and supporting drug product development. With significant advances in biomedical sciences and biotechnology, innovative techniques have emerged to enhance our understanding of transmucosal drug permeation. Among these, non-destructive optical methods, particularly confocal laser scanning microscopy (CLSM) and confocal Raman spectroscopy and near-infrared (NIR) spectroscopy, have shown great promise in studying the permeation of topical drug products. These optical methods can provide more detailed information on functional groups of drug compounds. For instance, CLSM in combination with other techniques such as transmission electron microscopy and scanning electron microscopy has been utilized to explore the corneal penetration pathways of labeled peptides and to examine changes in cytoskeletal structure and tight-junction permeability when exposed to penetration-enhancing agents [<xref rid="B143-pharmaceutics-17-00256" ref-type="bibr">143</xref>,<xref rid="B144-pharmaceutics-17-00256" ref-type="bibr">144</xref>,<xref rid="B145-pharmaceutics-17-00256" ref-type="bibr">145</xref>]. CLSM has also been employed to identify the transcellular routes through which various nanocapsules penetrate the cornea, both ex vivo and in vivo [<xref rid="B146-pharmaceutics-17-00256" ref-type="bibr">146</xref>]. In terms of nasal drug permeation, CLSM has provided valuable insights into the permeation and uptake mechanisms of therapeutic proteins, such as human calcitonin and insulin, through ex vivo nasal epithelia [<xref rid="B147-pharmaceutics-17-00256" ref-type="bibr">147</xref>,<xref rid="B148-pharmaceutics-17-00256" ref-type="bibr">148</xref>]. CLSM has also been utilized in elucidating the impact of size and polyethylene glycol (PEG) coating density on the transport of poly(lactic acid)&#8211;poly(ethylene glycol) (PLA&#8211;PEG) nanoparticles and microparticles across the nasal mucosa in rats [<xref rid="B149-pharmaceutics-17-00256" ref-type="bibr">149</xref>]. Oranat et.al used confocal Raman spectroscopy to measure the local concentrations of the topical vaginal anti-HIV microbicide (tenofovir) in fluids, drug delivery gels, and tissues. Their findings demonstrated a strong correlation between tenofovir tissue permeation obtained using confocal Raman spectroscopy and that obtained using LC-MS/MS [<xref rid="B150-pharmaceutics-17-00256" ref-type="bibr">150</xref>]. Furthermore, the combination of confocal Raman spectroscopy and optical coherence tomography (OCT) has enabled temporally and spatially specific measurements of tenofovir concentration across the full depth of excised porcine rectal mucosa [<xref rid="B151-pharmaceutics-17-00256" ref-type="bibr">151</xref>]. Despite its potential as a minimally invasive and label-free analytical tool for determining drug concentrations during the permeation process, confocal Raman spectroscopy has certain limitations: (1) high variability in tissue composition and structure, which can complicate Raman spectral analysis [<xref rid="B152-pharmaceutics-17-00256" ref-type="bibr">152</xref>]; and (2) ongoing diffusion and changes in tissue hydration during IVPT, which can alter Raman spectra. As a result, confocal Raman spectroscopy is still considered a semi-quantitative technique.</p><p>As drug delivery systems become more complex, IVPT is expected to evolve to include more sophisticated models, such as organ-on-a-chip systems, to replicate human physiological conditions more effectively. Recent efforts have focused on building models, such as a nasal epithelial mucosa, to mimic nasal tissue physiology in vitro [<xref rid="B153-pharmaceutics-17-00256" ref-type="bibr">153</xref>,<xref rid="B154-pharmaceutics-17-00256" ref-type="bibr">154</xref>] for drug transport studies of aerosols [<xref rid="B155-pharmaceutics-17-00256" ref-type="bibr">155</xref>]. Advanced tools such as the dynamic micro tissue engineering system (DynaMiTES) [<xref rid="B156-pharmaceutics-17-00256" ref-type="bibr">156</xref>] were used to build a 3D hemi-cornea construct composed of human keratocytes (HCKeCa) and epithelial cells (HCE-T) [<xref rid="B157-pharmaceutics-17-00256" ref-type="bibr">157</xref>]. Although this ocular tissue-on-a-chip model was developed to study the disease progression of macular degeneration, it could potentially be useful for studying drug permeability [<xref rid="B158-pharmaceutics-17-00256" ref-type="bibr">158</xref>,<xref rid="B159-pharmaceutics-17-00256" ref-type="bibr">159</xref>].</p><p>In vitro&#8211;in vivo correlation (IVIVC) is defined by the U.S. FDA as a predictive mathematical model describing the relationship between the in vitro properties of a dosage form and its relevant in vivo response. While IVIVC has been extensively developed for extended-release oral drug products, regulatory agencies currently do not permit the use of IVIVC as a surrogate for bioequivalence (BE) studies of locally acting transmucosal drug products. Recent advancements have demonstrated the feasibility of developing an IVIVC for dermatological products such as transdermal patches [<xref rid="B160-pharmaceutics-17-00256" ref-type="bibr">160</xref>]. For most percutaneous drug products, the rate-limiting step in absorption is drug transport across the stratum corneum (SC), rather than its release from a transdermal formulation. Similarly, the epithelium of mucosae may serve as the primary barrier to drug absorption in the mucosal membrane. This suggests that IVPT studies using exercised tissues with good integrity could potentially correlate well with in vivo absorption of transmucosal drugs. For systemically acting drug products, BE, required for generic drug approval, is evaluated based on plasma pharmacokinetic approaches, which can provide accurate and direct evidence through area under the plasma concentration curve (AUC) and maximum concentration (<italic toggle="yes">C<sub>max</sub></italic>). However, BE assessment for locally acting topical drug products often relies on costly comparative in vivo clinical endpoint studies, which can be challenging [<xref rid="B161-pharmaceutics-17-00256" ref-type="bibr">161</xref>]. Recognizing these challenges, the U.S. FDA has made significant efforts in recent years to provide guidance documents supporting in vitro characterization-based BE approaches to demonstrate BE for topical dermatological drug products [<xref rid="B162-pharmaceutics-17-00256" ref-type="bibr">162</xref>,<xref rid="B163-pharmaceutics-17-00256" ref-type="bibr">163</xref>,<xref rid="B164-pharmaceutics-17-00256" ref-type="bibr">164</xref>,<xref rid="B165-pharmaceutics-17-00256" ref-type="bibr">165</xref>,<xref rid="B166-pharmaceutics-17-00256" ref-type="bibr">166</xref>]. IVPT is a key component of the in vitro characterization-based BE approaches recommended in several product-specific guidance (PSG) for topical drug products to compare prospective generic products and reference drug products [<xref rid="B167-pharmaceutics-17-00256" ref-type="bibr">167</xref>,<xref rid="B168-pharmaceutics-17-00256" ref-type="bibr">168</xref>,<xref rid="B169-pharmaceutics-17-00256" ref-type="bibr">169</xref>,<xref rid="B170-pharmaceutics-17-00256" ref-type="bibr">170</xref>,<xref rid="B171-pharmaceutics-17-00256" ref-type="bibr">171</xref>]. The endpoints of IVPT are based on parameters that characterize the rate (flux, <italic toggle="yes">J</italic>) and extent (total cumulative amount, AMT) of drug permeation. The maximum flux (<italic toggle="yes">J<sub>max</sub></italic>) at the peak of the drug flux profile and the AMT should both be compared for locally acting test topical products and reference standards (RSs). This is somewhat analogous to the comparison of the <italic toggle="yes">C<sub>max</sub></italic> and AUC for systemically acting test products and RSs [<xref rid="B172-pharmaceutics-17-00256" ref-type="bibr">172</xref>]. Similar in vitro characterization-based approaches are currently under investigation for locally acting semisolid dosage forms administrated via mucosal routes, such as vaginal and rectal. Early evidence supports the feasibility of in vitro characterization-based BE approaches for locally acting transmucosal drug products [<xref rid="B173-pharmaceutics-17-00256" ref-type="bibr">173</xref>,<xref rid="B174-pharmaceutics-17-00256" ref-type="bibr">174</xref>,<xref rid="B175-pharmaceutics-17-00256" ref-type="bibr">175</xref>].</p><p>In silico prediction of mucosal drug permeation may be an alternative to experimental permeation studies in the future. Various in silico models, such as the Potts&#8211;Guy model, have been developed to correlate transdermal permeability coefficients and drug molecule characteristics (such as lipophilicity and MW) [<xref rid="B121-pharmaceutics-17-00256" ref-type="bibr">121</xref>]. Although there is currently no simple model to predict mucosal drug permeation, it is expected that this will be addressed in the near future with advances in physiologically based pharmacokinetic (PBPK) modeling.</p></sec><sec id="sec6-pharmaceutics-17-00256"><title>6. Summary and Outlook</title><p>IVPT has emerged as a pivotal tool in evaluating the performance of transmucosal drug products, offering insights into their absorption mechanisms and predicting in vivo drug behavior. The integration of IVPT with IVIVC for locally acting drug products, including those administered through the mucosal routes, holds significant potential for advancing regulatory science and streamlining drug approval processes. However, challenges remain, including variability in mucosal tissue properties and the need for standardized IVPT protocols. Continued refinement of more biorelevant and robust IVPT methodologies, coupled with advanced analytical tools and deeper insights into drug permeation mechanisms, is expected to drive the development of safer and more effective transmucosal drug products. As these methods become more standardized and validated, they are likely to play a crucial role in the FDA&#8217;s regulatory strategies, facilitating the development and approval of both innovator and generic transmucosal drug products, which will ultimately improve public access to medications.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to thank biorender.com for providing a platform for creating figures.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, J.S. (Juan Song), L.X. and J.S. (Jie Shen); writing&#8212;original draft preparation, J.S. (Juan Song), L.X., and Z.X.; writing&#8212;review and editing, J.S. (Jie Shen), Z.X., J.S. (Juan Song) and L.X.; supervision and funding acquisition, J.S. (Jie Shen). All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript.
<array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">BE</td><td align="left" valign="middle" rowspan="1" colspan="1">bioequivalence</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FDA</td><td align="left" valign="middle" rowspan="1" colspan="1">Food and Drug Administration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FTC</td><td align="left" valign="middle" rowspan="1" colspan="1">flow-through cell</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IVIVC</td><td align="left" valign="middle" rowspan="1" colspan="1">in vitro&#8211;in vivo correlation</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IVRT</td><td align="left" valign="middle" rowspan="1" colspan="1">in vitro release testing</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IVPT</td><td align="left" valign="middle" rowspan="1" colspan="1">in vitro permeation testing</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PSG</td><td align="left" valign="middle" rowspan="1" colspan="1">product-specific guidance</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TEER</td><td align="left" valign="middle" rowspan="1" colspan="1">transepithelial electrical resistance</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VDC</td><td align="left" valign="middle" rowspan="1" colspan="1">vertical diffusion cell</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00256"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hearnden</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sankar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hull</surname><given-names>K.</given-names></name><name name-style="western"><surname>Juras</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Patton</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thornhill</surname><given-names>M.H.</given-names></name></person-group><article-title>New developments and opportunities in oral mucosal drug delivery for local and systemic disease</article-title><source>Adv. Drug Deliv. Rev.</source><year>2012</year><volume>64</volume><fpage>16</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2011.02.008</pub-id><pub-id pub-id-type="pmid">21371513</pub-id></element-citation></ref><ref id="B2-pharmaceutics-17-00256"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Brunaugh</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>H.D.C.</given-names></name><name name-style="western"><surname>Williams Iii</surname><given-names>R.O.</given-names></name></person-group><article-title>Rectal and Vaginal Drug Delivery</article-title><source>Essential Pharmaceutics</source><person-group person-group-type="editor"><name name-style="western"><surname>Brunaugh</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>H.D.C.</given-names></name><name name-style="western"><surname>Williams Iii</surname><given-names>R.O.</given-names></name></person-group><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2019</year><fpage>149</fpage><lpage>161</lpage></element-citation></ref><ref id="B3-pharmaceutics-17-00256"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boddupalli</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>Z.N.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Banji</surname><given-names>D.</given-names></name></person-group><article-title>Mucoadhesive drug delivery system: An overview</article-title><source>J. Adv. Pharm. Technol. Res.</source><year>2010</year><volume>1</volume><fpage>381</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.4103/0110-5558.76436</pub-id><pub-id pub-id-type="pmid">22247877</pub-id><pub-id pub-id-type="pmcid">PMC3255397</pub-id></element-citation></ref><ref id="B4-pharmaceutics-17-00256"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laffleur</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bernkop-Schn&#252;rch</surname><given-names>A.</given-names></name></person-group><article-title>Strategies for improving mucosal drug delivery</article-title><source>Nanomedicine</source><year>2013</year><volume>8</volume><fpage>2061</fpage><lpage>2075</lpage><pub-id pub-id-type="doi">10.2217/nnm.13.178</pub-id><pub-id pub-id-type="pmid">24279493</pub-id></element-citation></ref><ref id="B5-pharmaceutics-17-00256"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Chastain</surname><given-names>J.</given-names></name></person-group><article-title>General Considerations in Ocular Drug Delivery</article-title><source>Ophthalmic Drug Delivery Systems</source><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2003</year><fpage>59</fpage><lpage>107</lpage></element-citation></ref><ref id="B6-pharmaceutics-17-00256"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Al-Ghabeish</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Krishnaiah</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Yerlikaya</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Manda</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.A.</given-names></name></person-group><article-title>Formulation and process factors influencing product quality and in vitro performance of ophthalmic ointments</article-title><source>Int. J. Pharm.</source><year>2015</year><volume>493</volume><fpage>412</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2015.07.066</pub-id><pub-id pub-id-type="pmid">26231106</pub-id></element-citation></ref><ref id="B7-pharmaceutics-17-00256"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Mitra</surname><given-names>A.K.</given-names></name></person-group><source>Ophthalmic Drug Delivery Systems, Second Edition, Revised and Expanded</source><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2003</year></element-citation></ref><ref id="B8-pharmaceutics-17-00256"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bitter</surname><given-names>C.</given-names></name><name name-style="western"><surname>Suter-Zimmermann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Surber</surname><given-names>C.</given-names></name></person-group><article-title>Nasal drug delivery in humans</article-title><source>Curr. Probl. Dermatol.</source><year>2011</year><volume>40</volume><fpage>20</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1159/000321044</pub-id><pub-id pub-id-type="pmid">21325837</pub-id></element-citation></ref><ref id="B9-pharmaceutics-17-00256"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beule</surname><given-names>A.G.</given-names></name></person-group><article-title>Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses</article-title><source>GMS Curr. Top. Otorhinolaryngol. Head Neck Surg.</source><year>2010</year><volume>9</volume><fpage>Doc07</fpage><pub-id pub-id-type="doi">10.3205/cto000071</pub-id><pub-id pub-id-type="pmid">22073111</pub-id><pub-id pub-id-type="pmcid">PMC3199822</pub-id></element-citation></ref><ref id="B10-pharmaceutics-17-00256"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eichner</surname><given-names>H.</given-names></name><name name-style="western"><surname>Behbehani</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Hochstrasser</surname><given-names>K.</given-names></name></person-group><article-title>Diagnostic value of nasal secretions, current state: Normal values. 1. [Nasensekretdiagnostik, aktueller Stand: Normalwerte. Teil 1]</article-title><source>Laryngol Laryngol. Rhinol. Otol.</source><year>1983</year><volume>62</volume><fpage>561</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1055/s-2007-1008498</pub-id><pub-id pub-id-type="pmid">6672496</pub-id></element-citation></ref><ref id="B11-pharmaceutics-17-00256"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hua</surname><given-names>S.</given-names></name></person-group><article-title>Physiological and Pharmaceutical Considerations for Rectal Drug Formulations</article-title><source>Front. Pharmacol.</source><year>2019</year><volume>10</volume><elocation-id>1196</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2019.01196</pub-id><pub-id pub-id-type="pmid">31680970</pub-id><pub-id pub-id-type="pmcid">PMC6805701</pub-id></element-citation></ref><ref id="B12-pharmaceutics-17-00256"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldwyn</surname><given-names>R.M.</given-names></name></person-group><article-title>Gray&#8217;s anatomy</article-title><source>Plast. Reconstr. Surg.</source><year>1985</year><volume>76</volume><fpage>147</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1097/00006534-198507000-00027</pub-id><pub-id pub-id-type="pmid">3892562</pub-id></element-citation></ref><ref id="B13-pharmaceutics-17-00256"><label>13.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Batchelor</surname><given-names>H.</given-names></name></person-group><article-title>Rectal Drug Delivery</article-title><source>Pediatric Formulations: A Roadmap</source><person-group person-group-type="editor"><name name-style="western"><surname>Bar-Shalom</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>K.</given-names></name></person-group><series>AAPS Advances in the Pharmaceutical Sciences Series</series><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2014</year><volume>11</volume><fpage>303</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1007/978-1-4899-8011-3_20</pub-id></element-citation></ref><ref id="B14-pharmaceutics-17-00256"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Marathe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pudney</surname><given-names>J.</given-names></name></person-group><article-title>The structure of the human vaginal stratum corneum and its role in immune defense</article-title><source>Am. J. Reprod. Immunol.</source><year>2014</year><volume>71</volume><fpage>618</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1111/aji.12230</pub-id><pub-id pub-id-type="pmid">24661416</pub-id><pub-id pub-id-type="pmcid">PMC4024347</pub-id></element-citation></ref><ref id="B15-pharmaceutics-17-00256"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owen</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>D.F.</given-names></name></person-group><article-title>A vaginal fluid simulant</article-title><source>Contraception</source><year>1999</year><volume>59</volume><fpage>91</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/S0010-7824(99)00010-4</pub-id><pub-id pub-id-type="pmid">10361623</pub-id></element-citation></ref><ref id="B16-pharmaceutics-17-00256"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>K.</given-names></name><name name-style="western"><surname>Agnew</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gaussman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Coombs</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Hitti</surname><given-names>J.</given-names></name></person-group><article-title>Estimating volume of cervicovaginal secretions in cervicovaginal lavage fluid collected for measurement of genital HIV-1 RNA levels in women</article-title><source>J. Clin. Microbiol.</source><year>2011</year><volume>49</volume><fpage>735</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1128/JCM.00991-10</pub-id><pub-id pub-id-type="pmid">21106793</pub-id><pub-id pub-id-type="pmcid">PMC3043490</pub-id></element-citation></ref><ref id="B17-pharmaceutics-17-00256"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maurice</surname><given-names>D.M.</given-names></name></person-group><article-title>The dynamics and drainage of tears</article-title><source>Int. Ophthalmol. Clin.</source><year>1973</year><volume>13</volume><fpage>103</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1097/00004397-197301310-00009</pub-id><pub-id pub-id-type="pmid">4724254</pub-id></element-citation></ref><ref id="B18-pharmaceutics-17-00256"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mishima</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gasset</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klyce</surname><given-names>S.D.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Baum</surname><given-names>J.L.</given-names></name></person-group><article-title>Determination of Tear Volume and Tear Flow</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>1966</year><volume>5</volume><fpage>264</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">5947945</pub-id></element-citation></ref><ref id="B19-pharmaceutics-17-00256"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ehlers</surname><given-names>N.</given-names></name></person-group><article-title>The precorneal film. Biomicroscopical, histological and chemical investigations</article-title><source>Acta Ophthalmol. Suppl.</source><year>1965</year><volume>81</volume><fpage>81</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">14298285</pub-id></element-citation></ref><ref id="B20-pharmaceutics-17-00256"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hornof</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toropainen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Urtti</surname><given-names>A.</given-names></name></person-group><article-title>Cell culture models of the ocular barriers</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2005</year><volume>60</volume><fpage>207</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2005.01.009</pub-id><pub-id pub-id-type="pmid">15939234</pub-id></element-citation></ref><ref id="B21-pharmaceutics-17-00256"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Schoenwald</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Lach</surname><given-names>J.L.</given-names></name></person-group><article-title>Corneal penetration behavior of beta-blocking agents III: In vitro-in vivo correlations</article-title><source>J. Pharm. Sci.</source><year>1983</year><volume>72</volume><fpage>1279</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.1002/jps.2600721108</pub-id><pub-id pub-id-type="pmid">6139473</pub-id></element-citation></ref><ref id="B22-pharmaceutics-17-00256"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klyce</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Crosson</surname><given-names>C.E.</given-names></name></person-group><article-title>Transport processes across the rabbit corneal epithelium: A review</article-title><source>Curr. Eye Res.</source><year>1985</year><volume>4</volume><fpage>323</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.3109/02713688509025145</pub-id><pub-id pub-id-type="pmid">3893897</pub-id></element-citation></ref><ref id="B23-pharmaceutics-17-00256"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLaughlin</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Caldwell</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>T.O.</given-names></name></person-group><article-title>Freeze-fracture quantitative comparison of rabbit corneal epithelial and endothelial membranes</article-title><source>Curr. Eye Res.</source><year>1985</year><volume>4</volume><fpage>951</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.3109/02713689509000002</pub-id><pub-id pub-id-type="pmid">4064735</pub-id></element-citation></ref><ref id="B24-pharmaceutics-17-00256"><label>24.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sunkara</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kompella</surname><given-names>U.</given-names></name></person-group><article-title>Membrane Transport Processes in the Eye</article-title><source>Ophthalmic Drug Delivery Systems</source><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2003</year><fpage>13</fpage><lpage>58</lpage></element-citation></ref><ref id="B25-pharmaceutics-17-00256"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veronesi</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Alhamami</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miedema</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ruiz-Cardozo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vannier</surname><given-names>M.W.</given-names></name></person-group><article-title>Imaging of intranasal drug delivery to the brain</article-title><source>Am. J. Nucl. Med. Mol. Imaging</source><year>2020</year><volume>10</volume><fpage>1</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">32211216</pub-id><pub-id pub-id-type="pmcid">PMC7076302</pub-id></element-citation></ref><ref id="B26-pharmaceutics-17-00256"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pires</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fortuna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>G.</given-names></name><name name-style="western"><surname>Falc&#227;o</surname><given-names>A.</given-names></name></person-group><article-title>Intranasal drug delivery: How, why and what for?</article-title><source>J. Pharm. Pharm. Sci.</source><year>2009</year><volume>12</volume><fpage>288</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.18433/J3NC79</pub-id><pub-id pub-id-type="pmid">20067706</pub-id></element-citation></ref><ref id="B27-pharmaceutics-17-00256"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaiswal</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Darekar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saudagar</surname><given-names>R.</given-names></name></person-group><article-title>A recent review on nasal microemulsion for treatment of cns disorder</article-title><source>Int. J. Curr. Pharm. Res.</source><year>2017</year><volume>9</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.22159/ijcpr.2017v9i4.20963</pub-id></element-citation></ref><ref id="B28-pharmaceutics-17-00256"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bedse</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sadique</surname><given-names>S.M.S.</given-names></name><name name-style="western"><surname>Kunde</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jaiswal</surname><given-names>S.</given-names></name></person-group><article-title>Drug Delivery on Rectal Absorption: Suppositories</article-title><source>Int. J. Pharm. Sci. Rev. Res.</source><year>2013</year><volume>21</volume><fpage>70</fpage><lpage>76</lpage></element-citation></ref><ref id="B29-pharmaceutics-17-00256"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costantino</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Illum</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brandt</surname><given-names>G.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Quay</surname><given-names>S.C.</given-names></name></person-group><article-title>Intranasal delivery: Physicochemical and therapeutic aspects</article-title><source>Int. J. Pharm.</source><year>2007</year><volume>337</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2007.03.025</pub-id><pub-id pub-id-type="pmid">17475423</pub-id></element-citation></ref><ref id="B30-pharmaceutics-17-00256"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merkus</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Verhoef</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Schipper</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Marttin</surname><given-names>E.</given-names></name></person-group><article-title>Nasal mucociliary clearance as a factor in nasal drug delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>1998</year><volume>29</volume><fpage>13</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/s0169-409x(97)00059-8</pub-id><pub-id pub-id-type="pmid">10837578</pub-id></element-citation></ref><ref id="B31-pharmaceutics-17-00256"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>N.</given-names></name></person-group><article-title>The nose and paranasal sinuses physiology and anatomy</article-title><source>Adv. Drug Deliv. Rev.</source><year>2001</year><volume>51</volume><fpage>5</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(01)00172-7</pub-id><pub-id pub-id-type="pmid">11516776</pub-id></element-citation></ref><ref id="B32-pharmaceutics-17-00256"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mygind</surname><given-names>N.</given-names></name></person-group><article-title>Structure and ultrastructure of the nose</article-title><source>Nasal Allergy</source><year>1979</year><volume>2</volume><fpage>3</fpage><lpage>38</lpage></element-citation></ref><ref id="B33-pharmaceutics-17-00256"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>David</surname><given-names>G.</given-names></name><name name-style="western"><surname>Puri</surname><given-names>V.</given-names></name></person-group><article-title>Ovulation in rhesus monkeys suppressed by intranasal administration of progesterone and norethisterone</article-title><source>Nature</source><year>1977</year><volume>270</volume><fpage>532</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1038/270532a0</pub-id><pub-id pub-id-type="pmid">413055</pub-id></element-citation></ref><ref id="B34-pharmaceutics-17-00256"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Herbst</surname><given-names>A.L.</given-names></name></person-group><source>Comprehensive Gynecology</source><publisher-name>Mosby Elsevier Health Science</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>1992</year></element-citation></ref><ref id="B35-pharmaceutics-17-00256"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sridhar</surname><given-names>M.S.</given-names></name></person-group><article-title>Anatomy of cornea and ocular surface</article-title><source>Indian J. Ophthalmol.</source><year>2018</year><volume>66</volume><fpage>190</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.4103/ijo.IJO_646_17</pub-id><pub-id pub-id-type="pmid">29380756</pub-id><pub-id pub-id-type="pmcid">PMC5819093</pub-id></element-citation></ref><ref id="B36-pharmaceutics-17-00256"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jannin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lemagnen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gueroult</surname><given-names>P.</given-names></name><name name-style="western"><surname>Larrouture</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tuleu</surname><given-names>C.</given-names></name></person-group><article-title>Rectal route in the 21st Century to treat children</article-title><source>Adv. Drug Deliv. Rev.</source><year>2014</year><volume>73</volume><fpage>34</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2014.05.012</pub-id><pub-id pub-id-type="pmid">24871671</pub-id></element-citation></ref><ref id="B37-pharmaceutics-17-00256"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Hoogdalem</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Boer</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Breimer</surname><given-names>D.D.</given-names></name></person-group><article-title>Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs</article-title><source>Clin. Pharmacokinet.</source><year>1991</year><volume>21</volume><fpage>11</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.2165/00003088-199121010-00002</pub-id><pub-id pub-id-type="pmid">1717195</pub-id></element-citation></ref><ref id="B38-pharmaceutics-17-00256"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sibinovska</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bo&#382;i&#269;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bo&#353;kovi&#263; Ribarski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kristan</surname><given-names>K.</given-names></name></person-group><article-title>Prediction of pharmacokinetic studies outcome for locally acting nasal sprays by using different in vitro methods</article-title><source>Int. J. Pharm.</source><year>2021</year><volume>601</volume><fpage>120569</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120569</pub-id><pub-id pub-id-type="pmid">33812972</pub-id></element-citation></ref><ref id="B39-pharmaceutics-17-00256"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nunes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sarmento</surname><given-names>B.</given-names></name><name name-style="western"><surname>das Neves</surname><given-names>J.</given-names></name></person-group><article-title>Formulation and delivery of anti-HIV rectal microbicides: Advances and challenges</article-title><source>J. Control Release</source><year>2014</year><volume>194</volume><fpage>278</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2014.09.013</pub-id><pub-id pub-id-type="pmid">25229988</pub-id></element-citation></ref><ref id="B40-pharmaceutics-17-00256"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Purohit</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Hanning</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name></person-group><article-title>Advances in rectal drug delivery systems</article-title><source>Pharm. Dev. Technol.</source><year>2018</year><volume>23</volume><fpage>942</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1080/10837450.2018.1484766</pub-id><pub-id pub-id-type="pmid">29888992</pub-id></element-citation></ref><ref id="B41-pharmaceutics-17-00256"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Boer</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Moolenaar</surname><given-names>F.</given-names></name><name name-style="western"><surname>de Leede</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Breimer</surname><given-names>D.D.</given-names></name></person-group><article-title>Rectal drug administration: Clinical pharmacokinetic considerations</article-title><source>Clin. Pharmacokinet.</source><year>1982</year><volume>7</volume><fpage>285</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.2165/00003088-198207040-00002</pub-id><pub-id pub-id-type="pmid">6126289</pub-id></element-citation></ref><ref id="B42-pharmaceutics-17-00256"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Hoogdalem</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>de Boer</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Breimer</surname><given-names>D.D.</given-names></name></person-group><article-title>Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions</article-title><source>Clin. Pharmacokinet.</source><year>1991</year><volume>21</volume><fpage>110</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.2165/00003088-199121020-00003</pub-id><pub-id pub-id-type="pmid">1884566</pub-id></element-citation></ref><ref id="B43-pharmaceutics-17-00256"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woolfson</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Malcolm</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>R.</given-names></name></person-group><article-title>Drug delivery by the intravaginal route</article-title><source>Crit. Rev. Ther. Drug Carrier Syst.</source><year>2000</year><volume>17</volume><fpage>509</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1615/CritRevTherDrugCarrierSyst.v17.i5.30</pub-id><pub-id pub-id-type="pmid">11108158</pub-id></element-citation></ref><ref id="B44-pharmaceutics-17-00256"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funt</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Birch</surname><given-names>H.</given-names></name></person-group><article-title>Normal vaginal axis</article-title><source>South. Med. J.</source><year>1978</year><volume>71</volume><fpage>1552</fpage><lpage>1535</lpage><page-range>1552, 1534&#8211;1535</page-range><pub-id pub-id-type="doi">10.1097/00007611-197812000-00026</pub-id><pub-id pub-id-type="pmid">725633</pub-id></element-citation></ref><ref id="B45-pharmaceutics-17-00256"><label>45.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Van De Graaff</surname><given-names>K.M.</given-names></name></person-group><source>Human Anatomy</source><publisher-name>McGraw-Hill Higher Education</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2001</year></element-citation></ref><ref id="B46-pharmaceutics-17-00256"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schuchner</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Foix</surname><given-names>A.</given-names></name><name name-style="western"><surname>Borenstein</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Marchese</surname><given-names>C.</given-names></name></person-group><article-title>Electron microscopy of human vaginal epithelium under normal and experimental conditions</article-title><source>J. Reprod. Fertil.</source><year>1974</year><volume>36</volume><fpage>231</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1530/jrf.0.0360231</pub-id><pub-id pub-id-type="pmid">4203601</pub-id></element-citation></ref><ref id="B47-pharmaceutics-17-00256"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sassi</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>McCullough</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Cost</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Hillier</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Rohan</surname><given-names>L.C.</given-names></name></person-group><article-title>Permeability of tritiated water through human cervical and vaginal tissue</article-title><source>J. Pharm. Sci.</source><year>2004</year><volume>93</volume><fpage>2009</fpage><lpage>2016</lpage><pub-id pub-id-type="doi">10.1002/jps.20107</pub-id><pub-id pub-id-type="pmid">15236450</pub-id></element-citation></ref><ref id="B48-pharmaceutics-17-00256"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohan</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Sassi</surname><given-names>A.B.</given-names></name></person-group><article-title>Vaginal drug delivery systems for HIV prevention</article-title><source>AAPS J.</source><year>2009</year><volume>11</volume><fpage>78</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1208/s12248-009-9082-7</pub-id><pub-id pub-id-type="pmid">19194802</pub-id><pub-id pub-id-type="pmcid">PMC2664883</pub-id></element-citation></ref><ref id="B49-pharmaceutics-17-00256"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paavonen</surname><given-names>J.</given-names></name></person-group><article-title>Physiology and ecology of the vagina</article-title><source>Scand. J. Infect. Dis. Suppl.</source><year>1983</year><volume>40</volume><fpage>31</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">6582587</pub-id></element-citation></ref><ref id="B50-pharmaceutics-17-00256"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brannon-Peppas</surname><given-names>L.</given-names></name></person-group><article-title>Novel vaginal drug release applications</article-title><source>Adv. Drug Deliv. Rev.</source><year>1993</year><volume>11</volume><fpage>169</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/0169-409X(93)90031-X</pub-id></element-citation></ref><ref id="B51-pharmaceutics-17-00256"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khanvilkar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Donovan</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>D.R.</given-names></name></person-group><article-title>Drug transfer through mucus</article-title><source>Adv. Drug Deliv. Rev.</source><year>2001</year><volume>48</volume><fpage>173</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(01)00115-6</pub-id><pub-id pub-id-type="pmid">11369081</pub-id></element-citation></ref><ref id="B52-pharmaceutics-17-00256"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoonen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moolenaar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Huizinga</surname><given-names>T.</given-names></name></person-group><article-title>Release of drugs from fatty suppository bases I. The release mechanism</article-title><source>Int. J. Pharm.</source><year>1979</year><volume>4</volume><fpage>141</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/0378-5173(79)90062-0</pub-id></element-citation></ref><ref id="B53-pharmaceutics-17-00256"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawson</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Norton</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Clements</surname><given-names>J.D.</given-names></name></person-group><article-title>Defending the mucosa: Adjuvant and carrier formulations for mucosal immunity</article-title><source>Curr. Opin. Immunol.</source><year>2011</year><volume>23</volume><fpage>414</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2011.03.009</pub-id><pub-id pub-id-type="pmid">21511452</pub-id></element-citation></ref><ref id="B54-pharmaceutics-17-00256"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shakya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Madhav</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Shakya</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K.</given-names></name></person-group><article-title>Palatal mucosa as a route for systemic drug delivery: A review</article-title><source>J. Control. Release</source><year>2011</year><volume>151</volume><fpage>2</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2010.11.003</pub-id><pub-id pub-id-type="pmid">21059376</pub-id></element-citation></ref><ref id="B55-pharmaceutics-17-00256"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mashru</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sutariya</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sankalia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sankalia</surname><given-names>J.</given-names></name></person-group><article-title>Transbuccal delivery of lamotrigine across porcine buccal mucosa: In vitro determination of routes of buccal transport</article-title><source>J. Pharm. Pharm. Sci.</source><year>2005</year><volume>8</volume><fpage>54</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15946598</pub-id></element-citation></ref><ref id="B56-pharmaceutics-17-00256"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensign</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Tse</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Hoen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cone</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hanes</surname><given-names>J.</given-names></name></person-group><article-title>Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus</article-title><source>Sci. Transl. Med.</source><year>2012</year><volume>4</volume><fpage>138ra79</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3003453</pub-id><pub-id pub-id-type="pmcid">PMC3817739</pub-id><pub-id pub-id-type="pmid">22700955</pub-id></element-citation></ref><ref id="B57-pharmaceutics-17-00256"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leithner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hauptstein</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hintzen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Salvenmoser</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bernkop-Schn&#252;rch</surname><given-names>A.</given-names></name></person-group><article-title>Preparation and characterization of mucus-penetrating papain/poly (acrylic acid) nanoparticles for oral drug delivery applications</article-title><source>J. Nanopart. Res.</source><year>2013</year><volume>15</volume><fpage>1353</fpage><pub-id pub-id-type="doi">10.1007/s11051-012-1353-z</pub-id></element-citation></ref><ref id="B58-pharmaceutics-17-00256"><label>58.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Shargel</surname><given-names>L.</given-names></name></person-group><source>Applied Biopharmaceutics &amp; Pharmacokinetics</source><edition>4th ed.</edition><publisher-name>Appleton &amp; Lange</publisher-name><publisher-loc>Stamford, CT, USA</publisher-loc><year>1999</year></element-citation></ref><ref id="B59-pharmaceutics-17-00256"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maren</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Jankowska</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Edelhauser</surname><given-names>H.F.</given-names></name></person-group><article-title>The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion</article-title><source>Exp. Eye Res.</source><year>1983</year><volume>36</volume><fpage>457</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1016/0014-4835(83)90041-6</pub-id><pub-id pub-id-type="pmid">6852128</pub-id></element-citation></ref><ref id="B60-pharmaceutics-17-00256"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leyva-G&#243;mez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Prado-Audelo</surname><given-names>M.L.D.</given-names></name><name name-style="western"><surname>Ortega-Pe&#241;a</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mendoza-Mu&#241;oz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Urb&#225;n-Morl&#225;n</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Torres</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Del Carmen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Figueroa-Gonz&#225;lez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reyes-Hern&#225;ndez</surname><given-names>O.D.</given-names></name><name name-style="western"><surname>Cort&#233;s</surname><given-names>H.</given-names></name></person-group><article-title>Modifications in Vaginal Microbiota and Their Influence on Drug Release: Challenges and Opportunities</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><elocation-id>217</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics11050217</pub-id><pub-id pub-id-type="pmid">31064154</pub-id><pub-id pub-id-type="pmcid">PMC6571606</pub-id></element-citation></ref><ref id="B61-pharmaceutics-17-00256"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franz</surname><given-names>T.J.</given-names></name></person-group><article-title>Percutaneous absorption on the relevance of in vitro data</article-title><source>J. Investig. Dermatol.</source><year>1975</year><volume>64</volume><fpage>190</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1111/1523-1747.ep12533356</pub-id><pub-id pub-id-type="pmid">123263</pub-id></element-citation></ref><ref id="B62-pharmaceutics-17-00256"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saettone</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Chetoni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cerbai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mazzanti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Braghiroli</surname><given-names>L.</given-names></name></person-group><article-title>Evaluation of ocular permeation enhancers: In vitro effects on corneal transport of four &#946;-blockers, and in vitro/in vivo toxic activity</article-title><source>Int. J. Pharm.</source><year>1996</year><volume>142</volume><fpage>103</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/0378-5173(96)04663-7</pub-id></element-citation></ref><ref id="B63-pharmaceutics-17-00256"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>H.</given-names></name></person-group><article-title>The effects of combined menthol and borneol on fluconazole permeation through the cornea ex vivo</article-title><source>Eur. J. Pharmacol.</source><year>2012</year><volume>688</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2011.12.007</pub-id><pub-id pub-id-type="pmid">22200629</pub-id></element-citation></ref><ref id="B64-pharmaceutics-17-00256"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ranta</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Laavola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toropainen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vellonen</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Talvitie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Urtti</surname><given-names>A.</given-names></name></person-group><article-title>Ocular pharmacokinetic modeling using corneal absorption and desorption rates from in vitro permeation experiments with cultured corneal epithelial cells</article-title><source>Pharm. Res.</source><year>2003</year><volume>20</volume><fpage>1409</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1023/A:1025754026449</pub-id><pub-id pub-id-type="pmid">14567635</pub-id></element-citation></ref><ref id="B65-pharmaceutics-17-00256"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reichl</surname><given-names>S.</given-names></name><name name-style="western"><surname>D&#246;hring</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bednarz</surname><given-names>J.</given-names></name><name name-style="western"><surname>M&#252;ller-Goymann</surname><given-names>C.C.</given-names></name></person-group><article-title>Human cornea construct HCC-an alternative for in vitro permeation studies? A comparison with human donor corneas</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2005</year><volume>60</volume><fpage>305</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2004.09.016</pub-id><pub-id pub-id-type="pmid">15939241</pub-id></element-citation></ref><ref id="B66-pharmaceutics-17-00256"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Ghabeish</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Krishnaiah</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.A.</given-names></name></person-group><article-title>Influence of drug loading and type of ointment base on the in vitro performance of acyclovir ophthalmic ointment</article-title><source>Int. J. Pharm.</source><year>2015</year><volume>495</volume><fpage>783</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2015.08.096</pub-id><pub-id pub-id-type="pmid">26343911</pub-id></element-citation></ref><ref id="B67-pharmaceutics-17-00256"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tegtmeyer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Papantoniou</surname><given-names>I.</given-names></name><name name-style="western"><surname>M&#252;ller-Goymann</surname><given-names>C.C.</given-names></name></person-group><article-title>Reconstruction of an in vitro cornea and its use for drug permeation studies from different formulations containing pilocarpine hydrochloride</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2001</year><volume>51</volume><fpage>119</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/S0939-6411(01)00123-0</pub-id><pub-id pub-id-type="pmid">11226818</pub-id></element-citation></ref><ref id="B68-pharmaceutics-17-00256"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richter</surname><given-names>T.</given-names></name><name name-style="western"><surname>Keipert</surname><given-names>S.</given-names></name></person-group><article-title>In vitro permeation studies comparing bovine nasal mucosa, porcine cornea and artificial membrane: Androstenedione in microemulsions and their components</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2004</year><volume>58</volume><fpage>137</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2004.03.010</pub-id><pub-id pub-id-type="pmid">15207547</pub-id></element-citation></ref><ref id="B69-pharmaceutics-17-00256"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toropainen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ranta</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Vellonen</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Palmgr&#233;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Talvitie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Laavola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Suhonen</surname><given-names>P.</given-names></name><name name-style="western"><surname>H&#228;m&#228;l&#228;inen</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Auriola</surname><given-names>S.</given-names></name><name name-style="western"><surname>Urtti</surname><given-names>A.</given-names></name></person-group><article-title>Paracellular and passive transcellular permeability in immortalized human corneal epithelial cell culture model</article-title><source>Eur. J. Pharm. Sci.</source><year>2003</year><volume>20</volume><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/S0928-0987(03)00173-8</pub-id><pub-id pub-id-type="pmid">13678798</pub-id></element-citation></ref><ref id="B70-pharmaceutics-17-00256"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inoue</surname><given-names>D.</given-names></name><name name-style="western"><surname>Furubayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sakane</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sugano</surname><given-names>K.</given-names></name></person-group><article-title>Quantitative estimation of drug permeation through nasal mucosa using in vitro membrane permeability across Calu-3 cell layers for predicting in vivo bioavailability after intranasal administration to rats</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2020</year><volume>149</volume><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2020.02.004</pub-id><pub-id pub-id-type="pmid">32057906</pub-id></element-citation></ref><ref id="B71-pharmaceutics-17-00256"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wengst</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reichl</surname><given-names>S.</given-names></name></person-group><article-title>RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2010</year><volume>74</volume><fpage>290</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2009.08.008</pub-id><pub-id pub-id-type="pmid">19733661</pub-id></element-citation></ref><ref id="B72-pharmaceutics-17-00256"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wadell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bj&#246;rk</surname><given-names>E.</given-names></name><name name-style="western"><surname>Camber</surname><given-names>O.</given-names></name></person-group><article-title>Permeability of porcine nasal mucosa correlated with human nasal absorption</article-title><source>Eur. J. Pharm. Sci.</source><year>2003</year><volume>18</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/S0928-0987(02)00240-3</pub-id><pub-id pub-id-type="pmid">12554072</pub-id></element-citation></ref><ref id="B73-pharmaceutics-17-00256"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Simmen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hilbe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boderke</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ditzinger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sandow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rubas</surname><given-names>W.</given-names></name><name name-style="western"><surname>Merkle</surname><given-names>H.P.</given-names></name></person-group><article-title>Validation of excised bovine nasal mucosa as in vitro model to study drug transport and metabolic pathways in nasal epithelium</article-title><source>J. Pharm. Sci.</source><year>2000</year><volume>89</volume><fpage>396</fpage><lpage>407</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1520-6017(200003)89:3&amp;#x0003c;396::AID-JPS10&amp;#x0003e;3.0.CO;2-F</pub-id><pub-id pub-id-type="pmid">10707019</pub-id></element-citation></ref><ref id="B74-pharmaceutics-17-00256"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pund</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rasve</surname><given-names>G.</given-names></name><name name-style="western"><surname>Borade</surname><given-names>G.</given-names></name></person-group><article-title>Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa</article-title><source>Eur. J. Pharm. Sci.</source><year>2013</year><volume>48</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2012.10.029</pub-id><pub-id pub-id-type="pmid">23159662</pub-id></element-citation></ref><ref id="B75-pharmaceutics-17-00256"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henriques</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bicker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Doktorovov&#225;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fortuna</surname><given-names>A.</given-names></name></person-group><article-title>Nasal-PAMPA: A novel non-cell-based high throughput screening assay for prediction of nasal drug permeability</article-title><source>Int. J. Pharm.</source><year>2023</year><volume>643</volume><fpage>123252</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2023.123252</pub-id><pub-id pub-id-type="pmid">37479103</pub-id></element-citation></ref><ref id="B76-pharmaceutics-17-00256"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivatsa Palakurthi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bharat Charbe</surname><given-names>N.</given-names></name><name name-style="western"><surname>Recalde Phillips</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Alge</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Palakurthi</surname><given-names>S.</given-names></name></person-group><article-title>Development of optimal in vitro release and permeation testing method for rectal suppositories</article-title><source>Int. J. Pharm.</source><year>2023</year><volume>640</volume><fpage>123042</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2023.123042</pub-id><pub-id pub-id-type="pmid">37178789</pub-id></element-citation></ref><ref id="B77-pharmaceutics-17-00256"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salem</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Rabea</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>El-Ela</surname><given-names>F.I.A.</given-names></name><name name-style="western"><surname>Khallaf</surname><given-names>R.A.</given-names></name></person-group><article-title>Glycerosomal thermosensitive in situ gel of duloxetine HCl as a novel nanoplatform for rectal delivery: In vitro optimization and in vivo appraisal</article-title><source>Drug Deliv. Transl. Res.</source><year>2022</year><volume>12</volume><fpage>3083</fpage><lpage>3103</lpage><pub-id pub-id-type="doi">10.1007/s13346-022-01172-z</pub-id><pub-id pub-id-type="pmid">35622235</pub-id><pub-id pub-id-type="pmcid">PMC9636110</pub-id></element-citation></ref><ref id="B78-pharmaceutics-17-00256"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanova</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Trapani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Mandracchia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Trapani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Franchini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corbo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tripodo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kolev</surname><given-names>I.N.</given-names></name><name name-style="western"><surname>Stoyanov</surname><given-names>G.S.</given-names></name><etal/></person-group><article-title>In vitro and ex vivo studies on diltiazem hydrochloride-loaded microsponges in rectal gels for chronic anal fissures treatment</article-title><source>Int. J. Pharm.</source><year>2019</year><volume>557</volume><fpage>53</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.12.039</pub-id><pub-id pub-id-type="pmid">30580086</pub-id></element-citation></ref><ref id="B79-pharmaceutics-17-00256"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eissa</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>El Sisi</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Bekhet</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>El-Ela</surname><given-names>F.I.A.</given-names></name><name name-style="western"><surname>Kharshoum</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Alrobaian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.M.A.</given-names></name></person-group><article-title>pH-Sensitive In Situ Gel of Mirtazapine Invasomes for Rectal Drug Delivery: Protruded Bioavailability and Anti-Depressant Efficacy</article-title><source>Pharmaceuticals</source><year>2024</year><volume>17</volume><elocation-id>978</elocation-id><pub-id pub-id-type="doi">10.3390/ph17080978</pub-id><pub-id pub-id-type="pmid">39204084</pub-id><pub-id pub-id-type="pmcid">PMC11357403</pub-id></element-citation></ref><ref id="B80-pharmaceutics-17-00256"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moawad</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>H.F.</given-names></name></person-group><article-title>Nanotransfersomes-loaded thermosensitive in situ gel as a rectal delivery system of tizanidine HCl: Preparation, in vitro and in vivo performance</article-title><source>Drug Deliv.</source><year>2017</year><volume>24</volume><fpage>252</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1080/10717544.2016.1245369</pub-id><pub-id pub-id-type="pmid">28156169</pub-id><pub-id pub-id-type="pmcid">PMC8241079</pub-id></element-citation></ref><ref id="B81-pharmaceutics-17-00256"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>das Neves</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ara&#250;jo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>F.</given-names></name><name name-style="western"><surname>Michiels</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ari&#235;n</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Vanham</surname><given-names>G.</given-names></name><name name-style="western"><surname>Amiji</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bahia</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Sarmento</surname><given-names>B.</given-names></name></person-group><article-title>In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine</article-title><source>Mol. Pharm.</source><year>2013</year><volume>10</volume><fpage>2793</fpage><lpage>2807</lpage><pub-id pub-id-type="doi">10.1021/mp4002365</pub-id><pub-id pub-id-type="pmid">23738946</pub-id></element-citation></ref><ref id="B82-pharmaceutics-17-00256"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nair</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bhargava</surname><given-names>H.N.</given-names></name></person-group><article-title>Comparison of in vitro dissolution and permeation of fluconazole from different suppository bases</article-title><source>Drug Dev. Ind. Pharm.</source><year>1999</year><volume>25</volume><fpage>691</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1081/DDC-100102227</pub-id><pub-id pub-id-type="pmid">10219541</pub-id></element-citation></ref><ref id="B83-pharmaceutics-17-00256"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bories</surname><given-names>C.</given-names></name><name name-style="western"><surname>Moal</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Loiseau</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Djabourov</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cortesi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bouchemal</surname><given-names>K.</given-names></name></person-group><article-title>Clotrimazole-loaded nanostructured lipid carrier hydrogels: Thermal analysis and in vitro studies</article-title><source>Int. J. Pharm.</source><year>2013</year><volume>454</volume><fpage>695</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.06.015</pub-id><pub-id pub-id-type="pmid">23792467</pub-id></element-citation></ref><ref id="B84-pharmaceutics-17-00256"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Eyk</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>van der Bijl</surname><given-names>P.</given-names></name></person-group><article-title>Porcine vaginal mucosa as an in vitro permeability model for human vaginal mucosa</article-title><source>Int. J. Pharm.</source><year>2005</year><volume>305</volume><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2005.09.002</pub-id><pub-id pub-id-type="pmid">16226413</pub-id></element-citation></ref><ref id="B85-pharmaceutics-17-00256"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCarron</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Gilmore</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Woolfson</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>McClelland</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zawislak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Price</surname><given-names>J.H.</given-names></name></person-group><article-title>Phototoxicity of 5-Aminolevulinic Acid in the HeLa Cell Line as an Indicative Measure of Photodynamic Effect After Topical Administration to Gynecological Lesions of Intraepithelial Form</article-title><source>Pharm. Res.</source><year>2004</year><volume>21</volume><fpage>1871</fpage><lpage>1879</lpage><pub-id pub-id-type="doi">10.1023/B:PHAM.0000045242.98628.0b</pub-id><pub-id pub-id-type="pmid">15553235</pub-id></element-citation></ref><ref id="B86-pharmaceutics-17-00256"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berginc</surname><given-names>K.</given-names></name><name name-style="western"><surname>Skalko-Basnet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Basnet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kristl</surname><given-names>A.</given-names></name></person-group><article-title>Development and evaluation of an in vitro vaginal model for assessment of drug&#8217;s biopharmaceutical properties: Curcumin</article-title><source>AAPS PharmSciTech</source><year>2012</year><volume>13</volume><fpage>1045</fpage><lpage>1053</lpage><pub-id pub-id-type="doi">10.1208/s12249-012-9837-9</pub-id><pub-id pub-id-type="pmid">22899381</pub-id><pub-id pub-id-type="pmcid">PMC3513450</pub-id></element-citation></ref><ref id="B87-pharmaceutics-17-00256"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sulistiawati</surname></name><name name-style="western"><surname>Enggi</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Isa</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Wijaya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ardika</surname><given-names>K.A.R.</given-names></name><name name-style="western"><surname>Asri</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Permana</surname><given-names>A.D.</given-names></name></person-group><article-title>Validation of spectrophotometric method to quantify cabotegravir in simulated vaginal fluid and porcine vaginal tissue in ex vivo permeation and retention studies from thermosensitive and mucoadhesive gels</article-title><source>Spectrochim. Acta Part A Mol. Biomol. Spectrosc.</source><year>2022</year><volume>267</volume><elocation-id>120600</elocation-id><pub-id pub-id-type="doi">10.1016/j.saa.2021.120600</pub-id><pub-id pub-id-type="pmid">34802927</pub-id></element-citation></ref><ref id="B88-pharmaceutics-17-00256"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machado</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Palmeira-de-Oliveira</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gaspar</surname><given-names>C.</given-names></name><name name-style="western"><surname>Martinez-de-Oliveira</surname><given-names>J.</given-names></name><name name-style="western"><surname>Palmeira-de-Oliveira</surname><given-names>R.</given-names></name></person-group><article-title>Studies and methodologies on vaginal drug permeation</article-title><source>Adv. Drug Deliv. Rev.</source><year>2015</year><volume>92</volume><fpage>14</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2015.02.003</pub-id><pub-id pub-id-type="pmid">25689736</pub-id></element-citation></ref><ref id="B89-pharmaceutics-17-00256"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>Proniosome-derived niosomes for tacrolimus topical ocular delivery: In vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection</article-title><source>Eur. J. Pharm. Sci.</source><year>2014</year><volume>62</volume><fpage>115</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2014.05.020</pub-id><pub-id pub-id-type="pmid">24905830</pub-id></element-citation></ref><ref id="B90-pharmaceutics-17-00256"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karasulu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yavaso&#287;lu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Evrensanal</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Uyanikgil</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Karasulu</surname><given-names>H.Y.</given-names></name></person-group><article-title>Permeation studies and histological examination of sheep nasal mucosa following administration of different nasal formulations with or without absorption enhancers</article-title><source>Drug Deliv.</source><year>2008</year><volume>15</volume><fpage>219</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1080/10717540802006377</pub-id><pub-id pub-id-type="pmid">18446567</pub-id></element-citation></ref><ref id="B91-pharmaceutics-17-00256"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehra</surname><given-names>N.</given-names></name><name name-style="western"><surname>Aqil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sultana</surname><given-names>Y.</given-names></name></person-group><article-title>A grafted copolymer-based nanomicelles for topical ocular delivery of everolimus: Formulation, characterization, ex-vivo permeation, in-vitro ocular toxicity, and stability study</article-title><source>Eur. J. Pharm. Sci.</source><year>2021</year><volume>159</volume><fpage>105735</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2021.105735</pub-id><pub-id pub-id-type="pmid">33516808</pub-id></element-citation></ref><ref id="B92-pharmaceutics-17-00256"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelbary</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Amin</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Zakaria</surname><given-names>M.Y.</given-names></name></person-group><article-title>Ocular ketoconazole-loaded proniosomal gels: Formulation, ex vivo corneal permeation and in vivo studies</article-title><source>Drug Deliv.</source><year>2017</year><volume>24</volume><fpage>309</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1080/10717544.2016.1247928</pub-id><pub-id pub-id-type="pmid">28165809</pub-id><pub-id pub-id-type="pmcid">PMC8241068</pub-id></element-citation></ref><ref id="B93-pharmaceutics-17-00256"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Resende</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>B.</given-names></name><name name-style="western"><surname>Braz</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gon&#231;alves</surname><given-names>L.</given-names></name><name name-style="western"><surname>Delgado</surname><given-names>E.</given-names></name></person-group><article-title>Ex vivo permeation of erythropoietin through porcine conjunctiva, cornea, and sclera</article-title><source>Drug Deliv. Transl. Res.</source><year>2017</year><volume>7</volume><fpage>625</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1007/s13346-017-0399-y</pub-id><pub-id pub-id-type="pmid">28639139</pub-id></element-citation></ref><ref id="B94-pharmaceutics-17-00256"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Fraissinette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kolopp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schiller</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fricker</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gammert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pospischil</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vonderscher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Richter</surname><given-names>F.</given-names></name></person-group><article-title>In vitro tolerability of human nasal mucosa: Histopathological and scanning electron-microscopic evaluation of nasal forms containing Sandostatin<sup>&#174;</sup></article-title><source>Cell Biol. Toxicol.</source><year>1995</year><volume>11</volume><fpage>295</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1007/BF00757627</pub-id><pub-id pub-id-type="pmid">8608410</pub-id></element-citation></ref><ref id="B95-pharmaceutics-17-00256"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Langguth</surname><given-names>P.</given-names></name><name name-style="western"><surname>Oschmann</surname><given-names>R.</given-names></name><name name-style="western"><surname>Traving</surname><given-names>B.</given-names></name><name name-style="western"><surname>Merkle</surname><given-names>H.P.</given-names></name></person-group><article-title>Transport and metabolic pathway of thymocartin (TP4) in excised bovine nasal mucosa</article-title><source>J. Pharm. Pharmacol.</source><year>1996</year><volume>48</volume><fpage>1190</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.1996.tb03919.x</pub-id><pub-id pub-id-type="pmid">8961171</pub-id></element-citation></ref><ref id="B96-pharmaceutics-17-00256"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ozkan</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Savaser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ozkan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tasdemir</surname><given-names>U.</given-names></name><name name-style="western"><surname>Altunay</surname><given-names>H.</given-names></name></person-group><article-title>Nasal administration of metoclopramide from different dosage forms: In vitro, ex vivo, and in vivo evaluation</article-title><source>Drug Deliv.</source><year>2009</year><volume>16</volume><fpage>167</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1080/10717540902764172</pub-id><pub-id pub-id-type="pmid">19514977</pub-id></element-citation></ref><ref id="B97-pharmaceutics-17-00256"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greimel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bernkop-Schn&#252;rch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Del Curto</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>D&#8217;Antonio</surname><given-names>M.</given-names></name></person-group><article-title>Transport characteristics of a beta sheet breaker peptide across excised bovine nasal mucosa</article-title><source>Drug Dev. Ind. Pharm.</source><year>2007</year><volume>33</volume><fpage>71</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1080/03639040600712953</pub-id><pub-id pub-id-type="pmid">17192253</pub-id></element-citation></ref><ref id="B98-pharmaceutics-17-00256"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osth</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gr&#229;sj&#246;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bj&#246;rk</surname><given-names>E.</given-names></name></person-group><article-title>A new method for drug transport studies on pig nasal mucosa using a horizontal Ussing chamber</article-title><source>J. Pharm. Sci.</source><year>2002</year><volume>91</volume><fpage>1259</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1002/jps.10123</pub-id><pub-id pub-id-type="pmid">11977102</pub-id></element-citation></ref><ref id="B99-pharmaceutics-17-00256"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Ara&#250;jo</surname><given-names>J.S.M.</given-names></name><name name-style="western"><surname>Augusto</surname><given-names>G.G.X.</given-names></name><name name-style="western"><surname>Pestana</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Groppo</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>F.S.M.</given-names></name><name name-style="western"><surname>Novaes</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Franz-Montan</surname><given-names>M.</given-names></name></person-group><article-title>Impact of Storage on In Vitro Permeation and Mucoadhesion Setup Experiments Using Swine Nasal Mucosa</article-title><source>AAPS PharmSciTech</source><year>2024</year><volume>26</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1208/s12249-024-03002-6</pub-id><pub-id pub-id-type="pmid">39638952</pub-id></element-citation></ref><ref id="B100-pharmaceutics-17-00256"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reardon</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Gochoco</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Audus</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>P.L.</given-names></name></person-group><article-title>In vitro nasal transport across ovine mucosa: Effects of ammonium glycyrrhizinate on electrical properties and permeability of growth hormone releasing peptide, mannitol, and lucifer yellow</article-title><source>Pharm. Res.</source><year>1993</year><volume>10</volume><fpage>553</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1023/A:1018997919115</pub-id><pub-id pub-id-type="pmid">8483838</pub-id></element-citation></ref><ref id="B101-pharmaceutics-17-00256"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sood</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gowthamarajan</surname><given-names>K.</given-names></name></person-group><article-title>Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment</article-title><source>Colloids Surf. B Biointerfaces</source><year>2014</year><volume>113</volume><fpage>330</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2013.09.030</pub-id><pub-id pub-id-type="pmid">24121076</pub-id></element-citation></ref><ref id="B102-pharmaceutics-17-00256"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>W.</given-names></name></person-group><article-title>The permeation of nalmefene hydrochloride across different regions of ovine nasal mucosa</article-title><source>Chem. Pharm. Bull.</source><year>2006</year><volume>54</volume><fpage>1722</fpage><lpage>1724</lpage><pub-id pub-id-type="doi">10.1248/cpb.54.1722</pub-id><pub-id pub-id-type="pmid">17139110</pub-id></element-citation></ref><ref id="B103-pharmaceutics-17-00256"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sacchetti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pasquali</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bettini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Massimo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>A.</given-names></name></person-group><article-title>Primary microparticles and agglomerates of morphine for nasal insufflation</article-title><source>J. Pharm. Sci.</source><year>2006</year><volume>95</volume><fpage>2553</fpage><lpage>2561</lpage><pub-id pub-id-type="doi">10.1002/jps.20604</pub-id><pub-id pub-id-type="pmid">16937333</pub-id></element-citation></ref><ref id="B104-pharmaceutics-17-00256"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bortolotti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Balducci</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Sonvico</surname><given-names>F.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>G.</given-names></name></person-group><article-title>In vitro permeation of desmopressin across rabbit nasal mucosa from liquid nasal sprays: The enhancing effect of potassium sorbate</article-title><source>Eur. J. Pharm. Sci.</source><year>2009</year><volume>37</volume><fpage>36</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2008.12.015</pub-id><pub-id pub-id-type="pmid">19162181</pub-id></element-citation></ref><ref id="B105-pharmaceutics-17-00256"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Basha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abd El-Alim</surname><given-names>S.H.</given-names></name></person-group><article-title>Development of a novel vesicular system using a binary mixture of sorbitan monostearate and polyethylene glycol fatty acid esters for rectal delivery of rutin</article-title><source>J. Liposome Res.</source><year>2013</year><volume>23</volume><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.3109/08982104.2012.727422</pub-id><pub-id pub-id-type="pmid">23083098</pub-id></element-citation></ref><ref id="B106-pharmaceutics-17-00256"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Verstraelen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Peremans</surname><given-names>K.</given-names></name><name name-style="western"><surname>Villeirs</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vermeire</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Vos</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mehuys</surname><given-names>E.</given-names></name><name name-style="western"><surname>Remon</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Vervaet</surname><given-names>C.</given-names></name></person-group><article-title>Vaginal distribution and retention of a multiparticulate drug delivery system, assessed by gamma scintigraphy and magnetic resonance imaging</article-title><source>Int. J. Pharm.</source><year>2012</year><volume>426</volume><fpage>44</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2012.01.006</pub-id><pub-id pub-id-type="pmid">22265911</pub-id></element-citation></ref><ref id="B107-pharmaceutics-17-00256"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moss</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Malone</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kopin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gilman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Butkyavichene</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Motamedi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring</article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>875</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1128/AAC.05662-11</pub-id><pub-id pub-id-type="pmid">22123689</pub-id><pub-id pub-id-type="pmcid">PMC3264253</pub-id></element-citation></ref><ref id="B108-pharmaceutics-17-00256"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vincent</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Bourne</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cowan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stanberry</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Motamedi</surname><given-names>M.</given-names></name></person-group><article-title>High resolution imaging of epithelial injury in the sheep cervicovaginal tract: A promising model for testing safety of candidate microbicides</article-title><source>Sex. Transm. Dis.</source><year>2009</year><volume>36</volume><fpage>312</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1097/OLQ.0b013e31819496e4</pub-id><pub-id pub-id-type="pmid">19295469</pub-id><pub-id pub-id-type="pmcid">PMC2675633</pub-id></element-citation></ref><ref id="B109-pharmaceutics-17-00256"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lane</surname><given-names>M.E.</given-names></name></person-group><article-title>In vitro permeation testing for the evaluation of drug delivery to the skin</article-title><source>Eur. J. Pharm. Sci.</source><year>2024</year><volume>201</volume><fpage>106873</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2024.106873</pub-id><pub-id pub-id-type="pmid">39121921</pub-id></element-citation></ref><ref id="B110-pharmaceutics-17-00256"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lestari</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Nicolazzo</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Finnin</surname><given-names>B.C.</given-names></name></person-group><article-title>A novel flow through diffusion cell for assessing drug transport across the buccal mucosa in vitro</article-title><source>J. Pharm. Sci.</source><year>2009</year><volume>98</volume><fpage>4577</fpage><lpage>4588</lpage><pub-id pub-id-type="doi">10.1002/jps.21772</pub-id><pub-id pub-id-type="pmid">19408309</pub-id></element-citation></ref><ref id="B111-pharmaceutics-17-00256"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Bashaw</surname><given-names>E.</given-names></name></person-group><article-title>In Vitro Skin Permeation Methodology for Over-The-Counter Topical Dermatologic Products</article-title><source>Ther. Innov. Regul. Sci.</source><year>2020</year><volume>54</volume><fpage>693</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1007/s43441-019-00104-3</pub-id><pub-id pub-id-type="pmid">33301148</pub-id></element-citation></ref><ref id="B112-pharmaceutics-17-00256"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clarke</surname><given-names>L.L.</given-names></name></person-group><article-title>A guide to Ussing chamber studies of mouse intestine</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><year>2009</year><volume>296</volume><fpage>G1151</fpage><lpage>G1166</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.90649.2008</pub-id><pub-id pub-id-type="pmid">19342508</pub-id><pub-id pub-id-type="pmcid">PMC2697950</pub-id></element-citation></ref><ref id="B113-pharmaceutics-17-00256"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sheppard</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Hug</surname><given-names>M.J.</given-names></name></person-group><article-title>Transepithelial electrical measurements with the Ussing chamber</article-title><source>J. Cyst. Fibros.</source><year>2004</year><volume>3</volume><issue>(Suppl. 2)</issue><fpage>123</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2004.05.026</pub-id><pub-id pub-id-type="pmid">15463943</pub-id></element-citation></ref><ref id="B114-pharmaceutics-17-00256"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>V.F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>M.B.</given-names></name></person-group><article-title>Modeling the oral cavity: In vitro and in vivo evaluations of buccal drug delivery systems</article-title><source>J. Control Release</source><year>2012</year><volume>161</volume><fpage>746</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2012.05.026</pub-id><pub-id pub-id-type="pmid">22626941</pub-id></element-citation></ref><ref id="B115-pharmaceutics-17-00256"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ussing</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Zerahn</surname><given-names>K.</given-names></name></person-group><article-title>Active transport of sodium as the source of electric current in the short-circuited isolated frog skin</article-title><source>Acta Physiol. Scand.</source><year>1951</year><volume>23</volume><fpage>110</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1111/j.1748-1716.1951.tb00800.x</pub-id><pub-id pub-id-type="pmid">14868510</pub-id></element-citation></ref><ref id="B116-pharmaceutics-17-00256"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shafaie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hutter</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Chau</surname><given-names>D.Y.</given-names></name></person-group><article-title>In Vitro Cell Models for Ophthalmic Drug Development Applications</article-title><source>Biores Open Access</source><year>2016</year><volume>5</volume><fpage>94</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1089/biores.2016.0008</pub-id><pub-id pub-id-type="pmid">27158563</pub-id><pub-id pub-id-type="pmcid">PMC4845647</pub-id></element-citation></ref><ref id="B117-pharmaceutics-17-00256"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoultz</surname><given-names>I.</given-names></name><name name-style="western"><surname>Keita</surname><given-names>&#197;.V.</given-names></name></person-group><article-title>The Intestinal Barrier and Current Techniques for the Assessment of Gut Permeability</article-title><source>Cells</source><year>2020</year><volume>9</volume><elocation-id>1909</elocation-id><pub-id pub-id-type="doi">10.3390/cells9081909</pub-id><pub-id pub-id-type="pmid">32824536</pub-id><pub-id pub-id-type="pmcid">PMC7463717</pub-id></element-citation></ref><ref id="B118-pharmaceutics-17-00256"><label>118.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Cabrera-P&#233;rez</surname><given-names>M.&#193;.</given-names></name><name name-style="western"><surname>Bermejo-Sanz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-&#193;lvarez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-&#193;lvarez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vera Lara</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chou Kam</surname><given-names>W.-H.</given-names></name></person-group><article-title>Chapter 2&#8212;Importance and applications of cell- and tissue-based in vitro models for drug permeability screening in early stages of drug development</article-title><source>Concepts and Models for Drug Permeability Studies</source><edition>2nd ed.</edition><person-group person-group-type="editor"><name name-style="western"><surname>Sarmento</surname><given-names>B.</given-names></name><name name-style="western"><surname>Leite Pereira</surname><given-names>C.</given-names></name><name name-style="western"><surname>Neves</surname><given-names>J.D.</given-names></name></person-group><publisher-name>Woodhead Publishing</publisher-name><publisher-loc>Cambridge, UK</publisher-loc><year>2024</year><fpage>5</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/B978-0-443-15510-9.00017-7</pub-id></element-citation></ref><ref id="B119-pharmaceutics-17-00256"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Notara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>J.T.</given-names></name></person-group><article-title>Characterisation and functional features of a spontaneously immortalised human corneal epithelial cell line with progenitor-like characteristics</article-title><source>Brain Res. Bull.</source><year>2010</year><volume>81</volume><fpage>279</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2009.08.009</pub-id><pub-id pub-id-type="pmid">19699783</pub-id></element-citation></ref><ref id="B120-pharmaceutics-17-00256"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Araki-Sasaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sasabe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Handa</surname><given-names>H.</given-names></name></person-group><article-title>An SV40-immortalized human corneal epithelial cell line and its characterization</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>1995</year><volume>36</volume><fpage>614</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">7534282</pub-id></element-citation></ref><ref id="B121-pharmaceutics-17-00256"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohan</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Possin</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Mohan</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>S.E.</given-names></name></person-group><article-title>Development of genetically engineered tet HPV16-E6/E7 transduced human corneal epithelial clones having tight regulation of proliferation and normal differentiation</article-title><source>Exp. Eye Res.</source><year>2003</year><volume>77</volume><fpage>395</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/S0014-4835(03)00175-1</pub-id><pub-id pub-id-type="pmid">12957140</pub-id></element-citation></ref><ref id="B122-pharmaceutics-17-00256"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reichl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bednarz</surname><given-names>J.</given-names></name><name name-style="western"><surname>M&#252;ller-Goymann</surname><given-names>C.C.</given-names></name></person-group><article-title>Human corneal equivalent as cell culture model for in vitro drug permeation studies</article-title><source>Br. J. Ophthalmol.</source><year>2004</year><volume>88</volume><fpage>560</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1136/bjo.2003.028225</pub-id><pub-id pub-id-type="pmid">15031177</pub-id><pub-id pub-id-type="pmcid">PMC1772077</pub-id></element-citation></ref><ref id="B123-pharmaceutics-17-00256"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarmento</surname><given-names>B.</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>F.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>F.</given-names></name><name name-style="western"><surname>das Neves</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>D.</given-names></name></person-group><article-title>Cell-based in vitro models for predicting drug permeability</article-title><source>Expert. Opin. Drug Metab. Toxicol.</source><year>2012</year><volume>8</volume><fpage>607</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1517/17425255.2012.673586</pub-id><pub-id pub-id-type="pmid">22424145</pub-id></element-citation></ref><ref id="B124-pharmaceutics-17-00256"><label>124.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Cabrera-P&#233;rez</surname><given-names>M.&#193;.</given-names></name><name name-style="western"><surname>Sanz</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Sanjuan</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-&#193;lvarez</surname><given-names>M.</given-names></name><name name-style="western"><surname>&#193;lvarez</surname><given-names>I.G.</given-names></name></person-group><article-title>Importance and applications of cell- and tissue-based in vitro models for drug permeability screening in early stages of drug development</article-title><source>Concepts and Models for Drug Permeability Studies: Cell and Tissue Based In Vitro Culture Models</source><publisher-name>Woodhead Publishing</publisher-name><publisher-loc>Cambridge, UK</publisher-loc><year>2016</year><fpage>3</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/B978-0-08-100094-6.00002-X</pub-id></element-citation></ref><ref id="B125-pharmaceutics-17-00256"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorodeski</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Eckert</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Utian</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Rorke</surname><given-names>E.A.</given-names></name></person-group><article-title>Maintenance of in vivo-like keratin expression, sex steroid responsiveness, and estrogen receptor expression in cultured human ectocervical epithelial cells</article-title><source>Endocrinology</source><year>1990</year><volume>126</volume><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1210/endo-126-1-399</pub-id><pub-id pub-id-type="pmid">1688411</pub-id></element-citation></ref><ref id="B126-pharmaceutics-17-00256"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorodeski</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Hopfer</surname><given-names>U.</given-names></name><name name-style="western"><surname>Rorke</surname><given-names>E.</given-names></name><name name-style="western"><surname>Utian</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Eckert</surname><given-names>R.L.</given-names></name></person-group><article-title>Human uterine cervical epithelial cells grown on permeable support&#8212;A new model for the study of differentiation</article-title><source>Differentiation</source><year>1994</year><volume>56</volume><fpage>107</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1046/j.1432-0436.1994.56120107.x</pub-id><pub-id pub-id-type="pmid">7517899</pub-id></element-citation></ref><ref id="B127-pharmaceutics-17-00256"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuramoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Notake</surname><given-names>Y.</given-names></name></person-group><article-title>Establishment of a cell line of human endometrial adenocarcinoma in vitro</article-title><source>Am. J. Obstet. Gynecol.</source><year>1972</year><volume>114</volume><fpage>1012</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1016/0002-9378(72)90861-7</pub-id><pub-id pub-id-type="pmid">4673779</pub-id></element-citation></ref><ref id="B128-pharmaceutics-17-00256"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaushal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Trombetta</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ochs</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>J.</given-names></name></person-group><article-title>Delivery of TEM beta-lactamase by gene-transformed Lactococcus lactis subsp. lactis through cervical cell monolayer</article-title><source>Int. J. Pharm.</source><year>2006</year><volume>313</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2006.01.013</pub-id><pub-id pub-id-type="pmid">16488095</pub-id></element-citation></ref><ref id="B129-pharmaceutics-17-00256"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gali</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ari&#235;n</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Praet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van den Bergh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Temmerman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Delezay</surname><given-names>O.</given-names></name><name name-style="western"><surname>Vanham</surname><given-names>G.</given-names></name></person-group><article-title>Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity</article-title><source>J. Virol. Methods</source><year>2010</year><volume>165</volume><fpage>186</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2010.01.018</pub-id><pub-id pub-id-type="pmid">20138087</pub-id></element-citation></ref><ref id="B130-pharmaceutics-17-00256"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>McCormick</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Doncel</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Friend</surname><given-names>D.R.</given-names></name></person-group><article-title>Preclinical evaluation of UC781 microbicide vaginal drug delivery</article-title><source>Drug Deliv. Transl. Res.</source><year>2011</year><volume>1</volume><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1007/s13346-011-0019-1</pub-id><pub-id pub-id-type="pmid">25788115</pub-id></element-citation></ref><ref id="B131-pharmaceutics-17-00256"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Korting</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Borelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hamm</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hube</surname><given-names>B.</given-names></name></person-group><article-title>Candida albicans-secreted aspartic proteinases modify the epithelial cytokine response in an in vitro model of vaginal candidiasis</article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>2758</fpage><lpage>2765</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.5.2758-2765.2005</pub-id><pub-id pub-id-type="pmid">15845479</pub-id><pub-id pub-id-type="pmcid">PMC1087327</pub-id></element-citation></ref><ref id="B132-pharmaceutics-17-00256"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Korting</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Baur</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hamm</surname><given-names>G.</given-names></name><name name-style="western"><surname>Monod</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beinhauer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hube</surname><given-names>B.</given-names></name></person-group><article-title>The secreted aspartyl proteinases Sap1 and Sap2 cause tissue damage in an in vitro model of vaginal candidiasis based on reconstituted human vaginal epithelium</article-title><source>Infect. Immun.</source><year>2003</year><volume>71</volume><fpage>3227</fpage><lpage>3234</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.6.3227-3234.2003</pub-id><pub-id pub-id-type="pmid">12761103</pub-id><pub-id pub-id-type="pmcid">PMC155757</pub-id></element-citation></ref><ref id="B133-pharmaceutics-17-00256"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Cruz</surname><given-names>O.J.</given-names></name><name name-style="western"><surname>Uckun</surname><given-names>F.M.</given-names></name></person-group><article-title>Mucosal safety of PHI-443 and stampidine as a combination microbicide to prevent genital transmission of HIV-1</article-title><source>Fertil. Steril.</source><year>2007</year><volume>88</volume><fpage>1197</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2007.01.131</pub-id><pub-id pub-id-type="pmid">17498709</pub-id></element-citation></ref><ref id="B134-pharmaceutics-17-00256"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toropainen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ranta</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Talvitie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suhonen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Urtti</surname><given-names>A.</given-names></name></person-group><article-title>Culture model of human corneal epithelium for prediction of ocular drug absorption</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2001</year><volume>42</volume><fpage>2942</fpage><lpage>2948</lpage><pub-id pub-id-type="pmid">11687540</pub-id></element-citation></ref><ref id="B135-pharmaceutics-17-00256"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamasaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Young</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Fukuoka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tanioka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakatsukasa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Quantock</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>S.</given-names></name></person-group><article-title>Genomic aberrations and cellular heterogeneity in SV40-immortalized human corneal epithelial cells</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2009</year><volume>50</volume><fpage>604</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1167/iovs.08-2239</pub-id><pub-id pub-id-type="pmid">18824731</pub-id></element-citation></ref><ref id="B136-pharmaceutics-17-00256"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimova</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brewster</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Noppe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jorissen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Augustijns</surname><given-names>P.</given-names></name></person-group><article-title>The use of human nasal in vitro cell systems during drug discovery and development</article-title><source>Toxicol. In Vitro</source><year>2005</year><volume>19</volume><fpage>107</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.tiv.2004.07.003</pub-id><pub-id pub-id-type="pmid">15582362</pub-id></element-citation></ref><ref id="B137-pharmaceutics-17-00256"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Fraissinette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brun</surname><given-names>R.</given-names></name><name name-style="western"><surname>Felix</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vonderscher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rummelt</surname><given-names>A.</given-names></name></person-group><article-title>Evaluation of the human cell line RPMI 2650 as an in vitro nasal model</article-title><source>Rhinology</source><year>1995</year><volume>33</volume><fpage>194</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">8919210</pub-id></element-citation></ref><ref id="B138-pharmaceutics-17-00256"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Werner</surname><given-names>U.</given-names></name><name name-style="western"><surname>Kissel</surname><given-names>T.</given-names></name></person-group><article-title>In-vitro cell culture models of the nasal epithelium: A comparative histochemical investigation of their suitability for drug transport studies</article-title><source>Pharm. Res.</source><year>1996</year><volume>13</volume><fpage>978</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1023/A:1016038119909</pub-id><pub-id pub-id-type="pmid">8842033</pub-id></element-citation></ref><ref id="B139-pharmaceutics-17-00256"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorodeski</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Merlin</surname><given-names>D.</given-names></name><name name-style="western"><surname>De Santis</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Frieden</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Hopfer</surname><given-names>U.</given-names></name><name name-style="western"><surname>Eckert</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Utian</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>M.F.</given-names></name></person-group><article-title>Characterization of paracellular permeability in cultured human cervical epithelium: Regulation by extracellular adenosine triphosphate</article-title><source>J. Soc. Gynecol. Investig.</source><year>1994</year><volume>1</volume><fpage>225</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1177/107155769400100309</pub-id><pub-id pub-id-type="pmid">9419776</pub-id></element-citation></ref><ref id="B140-pharmaceutics-17-00256"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higuchi</surname><given-names>T.</given-names></name></person-group><article-title>Physical chemical analysis of percutaneous absorption process from creams and ointments</article-title><source>J. Soc. Cosmet. Chem.</source><year>1960</year><volume>11</volume><fpage>85</fpage><lpage>97</lpage></element-citation></ref><ref id="B141-pharmaceutics-17-00256"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitragotri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Anissimov</surname><given-names>Y.G.</given-names></name><name name-style="western"><surname>Bunge</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Frasch</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Guy</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Hadgraft</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kasting</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Lane</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>M.S.</given-names></name></person-group><article-title>Mathematical models of skin permeability: An overview</article-title><source>Int. J. Pharm.</source><year>2011</year><volume>418</volume><fpage>115</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2011.02.023</pub-id><pub-id pub-id-type="pmid">21356301</pub-id></element-citation></ref><ref id="B142-pharmaceutics-17-00256"><label>142.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Anissimov</surname><given-names>Y.G.</given-names></name></person-group><article-title>Mathematical models in percutaneous absorption</article-title><source>Percutaneous Absorption</source><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2005</year><fpage>37</fpage><lpage>80</lpage></element-citation></ref><ref id="B143-pharmaceutics-17-00256"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojanasakul</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Paddock</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>J.R.</given-names></name></person-group><article-title>Confocal laser scanning microscopic examination of transport pathways and barriers of some peptides across the cornea</article-title><source>Int. J. Pharm.</source><year>1990</year><volume>61</volume><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/0378-5173(90)90205-I</pub-id></element-citation></ref><ref id="B144-pharmaceutics-17-00256"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojanasakul</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liaw</surname><given-names>J.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>J.R.</given-names></name></person-group><article-title>Mechanisms of action of some penetration enhancers in the cornea: Laser scanning confocal microscopic and electrophysiology studies</article-title><source>Int. J. Pharm.</source><year>1990</year><volume>66</volume><fpage>131</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/0378-5173(90)90392-H</pub-id></element-citation></ref><ref id="B145-pharmaceutics-17-00256"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojanasakul</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>J.R.</given-names></name></person-group><article-title>The cytoskeleton of the cornea and its role in tight junction permeability</article-title><source>Int. J. Pharm.</source><year>1991</year><volume>68</volume><fpage>135</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/0378-5173(91)90136-C</pub-id></element-citation></ref><ref id="B146-pharmaceutics-17-00256"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Campos</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gref</surname><given-names>R.</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>M.J.</given-names></name></person-group><article-title>The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa</article-title><source>Eur. J. Pharm. Sci.</source><year>2003</year><volume>20</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/S0928-0987(03)00178-7</pub-id><pub-id pub-id-type="pmid">13678795</pub-id></element-citation></ref><ref id="B147-pharmaceutics-17-00256"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Rothen-Rutishauser</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rist</surname><given-names>B.</given-names></name><name name-style="western"><surname>Beck-Sickinger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wunderli-Allenspach</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rubas</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sad&#233;e</surname><given-names>W.</given-names></name><name name-style="western"><surname>Merkle</surname><given-names>H.P.</given-names></name></person-group><article-title>Translocation of human calcitonin in respiratory nasal epithelium is associated with self-assembly in lipid membrane</article-title><source>Biochemistry</source><year>1998</year><volume>37</volume><fpage>16582</fpage><lpage>16590</lpage><pub-id pub-id-type="doi">10.1021/bi981219h</pub-id><pub-id pub-id-type="pmid">9843425</pub-id></element-citation></ref><ref id="B148-pharmaceutics-17-00256"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rothen-Rutishauser</surname><given-names>B.</given-names></name><name name-style="western"><surname>Perriard</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Merkle</surname><given-names>H.P.</given-names></name></person-group><article-title>Permeation and pathways of human calcitonin (hCT) across excised bovine nasal mucosa</article-title><source>Peptides</source><year>1998</year><volume>19</volume><fpage>599</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1016/S0196-9781(97)00470-1</pub-id><pub-id pub-id-type="pmid">9533651</pub-id></element-citation></ref><ref id="B149-pharmaceutics-17-00256"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vila</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>H.</given-names></name><name name-style="western"><surname>McCallion</surname><given-names>O.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>M.J.</given-names></name></person-group><article-title>Transport of PLA-PEG particles across the nasal mucosa: Effect of particle size and PEG coating density</article-title><source>J. Control Release</source><year>2004</year><volume>98</volume><fpage>231</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2004.04.026</pub-id><pub-id pub-id-type="pmid">15262415</pub-id></element-citation></ref><ref id="B150-pharmaceutics-17-00256"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chuchuen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Sykes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kashuba</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>D.F.</given-names></name></person-group><article-title>Quantitative analysis of microbicide concentrations in fluids, gels and tissues using confocal Raman spectroscopy</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e85124</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0085124</pub-id><pub-id pub-id-type="pmid">24386455</pub-id><pub-id pub-id-type="pmcid">PMC3875564</pub-id></element-citation></ref><ref id="B151-pharmaceutics-17-00256"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Presnell</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Chuchuen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Simons</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Maher</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>D.F.</given-names></name></person-group><article-title>Full depth measurement of tenofovir transport in rectal mucosa using confocal Raman spectroscopy and optical coherence tomography</article-title><source>Drug Deliv. Transl. Res.</source><year>2018</year><volume>8</volume><fpage>843</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1007/s13346-018-0495-7</pub-id><pub-id pub-id-type="pmid">29468424</pub-id><pub-id pub-id-type="pmcid">PMC6042643</pub-id></element-citation></ref><ref id="B152-pharmaceutics-17-00256"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franzen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Windbergs</surname><given-names>M.</given-names></name></person-group><article-title>Applications of Raman spectroscopy in skin research&#8212;From skin physiology and diagnosis up to risk assessment and dermal drug delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>2015</year><volume>89</volume><fpage>91</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2015.04.002</pub-id><pub-id pub-id-type="pmid">25868454</pub-id></element-citation></ref><ref id="B153-pharmaceutics-17-00256"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Na</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>H.-W.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>S.</given-names></name></person-group><article-title>In vitro nasal mucosa gland-like structure formation on a chip</article-title><source>Lab Chip</source><year>2017</year><volume>17</volume><fpage>1578</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1039/C6LC01564F</pub-id><pub-id pub-id-type="pmid">28379223</pub-id></element-citation></ref><ref id="B154-pharmaceutics-17-00256"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.P.</given-names></name></person-group><article-title>Live human nasal epithelial cells (hNECs) on chip for in vitro testing of gaseous formaldehyde toxicity via airway delivery</article-title><source>Lab Chip</source><year>2014</year><volume>14</volume><fpage>677</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1039/C3LC51208H</pub-id><pub-id pub-id-type="pmid">24356185</pub-id></element-citation></ref><ref id="B155-pharmaceutics-17-00256"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gholizadeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kourmatzis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Traini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Young</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sheikh</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>H.X.</given-names></name></person-group><article-title>In vitro interactions of aerosol formulations with human nasal epithelium using real-time monitoring of drug transport in a nasal mucosa-on-a-chip</article-title><source>Biosens. Bioelectron.</source><year>2023</year><volume>223</volume><elocation-id>115010</elocation-id><pub-id pub-id-type="doi">10.1016/j.bios.2022.115010</pub-id><pub-id pub-id-type="pmid">36586150</pub-id></element-citation></ref><ref id="B156-pharmaceutics-17-00256"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattern</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bei&#223;ner</surname><given-names>N.</given-names></name><name name-style="western"><surname>Reichl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dietzel</surname><given-names>A.</given-names></name></person-group><article-title>DynaMiTES&#8212;A dynamic cell culture platform for in vitro drug testing PART 1&#8212;Engineering of microfluidic system and technical simulations</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2018</year><volume>126</volume><fpage>159</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2017.04.022</pub-id><pub-id pub-id-type="pmid">28442371</pub-id></element-citation></ref><ref id="B157-pharmaceutics-17-00256"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bei&#946;ner</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mattern</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dietzel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reichl</surname><given-names>S.</given-names></name></person-group><article-title>DynaMiTES&#8212;A dynamic cell culture platform for in vitro drug testing PART 2&#8212;Ocular DynaMiTES for drug absorption studies of the anterior eye</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2018</year><volume>126</volume><fpage>166</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2017.03.021</pub-id><pub-id pub-id-type="pmid">28377274</pub-id></element-citation></ref><ref id="B158-pharmaceutics-17-00256"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.-J.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nagamine</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nagai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nishizawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kaji</surname><given-names>H.</given-names></name></person-group><article-title>Microfluidic co-cultures of retinal pigment epithelial cells and vascular endothelial cells to investigate choroidal angiogenesis</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>3538</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-03788-5</pub-id><pub-id pub-id-type="pmid">28615726</pub-id><pub-id pub-id-type="pmcid">PMC5471206</pub-id></element-citation></ref><ref id="B159-pharmaceutics-17-00256"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Son</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name></person-group><article-title>Wet-AMD on a Chip: Modeling Outer Blood-Retinal Barrier In Vitro</article-title><source>Adv. Healthc. Mater.</source><year>2018</year><volume>7</volume><fpage>1700028</fpage><pub-id pub-id-type="doi">10.1002/adhm.201700028</pub-id><pub-id pub-id-type="pmid">28557377</pub-id></element-citation></ref><ref id="B160-pharmaceutics-17-00256"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kondamudi</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Tirumalasetty</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Malayandi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mutalik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pillai</surname><given-names>R.</given-names></name></person-group><article-title>Lidocaine Transdermal Patch: Pharmacokinetic Modeling and In Vitro-In Vivo Correlation (IVIVC)</article-title><source>AAPS PharmSciTech</source><year>2016</year><volume>17</volume><fpage>588</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1208/s12249-015-0390-1</pub-id><pub-id pub-id-type="pmid">26283198</pub-id></element-citation></ref><ref id="B161-pharmaceutics-17-00256"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baynes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Riviere</surname><given-names>J.</given-names></name><name name-style="western"><surname>Franz</surname><given-names>T.</given-names></name><name name-style="western"><surname>Monteiro-Riviere</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lehman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Peyrou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toutain</surname><given-names>P.L.</given-names></name></person-group><article-title>Challenges obtaining a biowaiver for topical veterinary dosage forms</article-title><source>J. Vet. Pharmacol. Ther.</source><year>2012</year><volume>35</volume><issue>(Suppl. 1)</issue><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2885.2012.01381.x</pub-id><pub-id pub-id-type="pmid">22413798</pub-id></element-citation></ref><ref id="B162-pharmaceutics-17-00256"><label>162.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. Food and Drug Administration</collab></person-group><article-title>Draft Product Specific Guidance on Acyclovir Ointment. Guidance Index</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018604.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018604.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-30">(accessed on 30 December 2024)</date-in-citation></element-citation></ref><ref id="B163-pharmaceutics-17-00256"><label>163.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. Food and Drug Administration</collab></person-group><article-title>Draft Product Specific Guidance on Acyclovir Cream. Guidance Index</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021478.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021478.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-30">(accessed on 30 December 2024)</date-in-citation></element-citation></ref><ref id="B164-pharmaceutics-17-00256"><label>164.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. Food and Drug Administration</collab></person-group><article-title>Draft Guidance on Penciclovir. Guidance Index</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020629.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020629.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-30">(accessed on 30 December 2024)</date-in-citation></element-citation></ref><ref id="B165-pharmaceutics-17-00256"><label>165.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. Food and Drug Administration</collab></person-group><article-title>Draft Guidance on Tacrolimus. Guidance Index</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050777.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050777.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-30">(accessed on 30 December 2024)</date-in-citation></element-citation></ref><ref id="B166-pharmaceutics-17-00256"><label>166.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. Food and Drug Administration</collab></person-group><article-title>Draft Guidance on Oxymetazoline Hydrochloride. Guidance Index</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208552.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208552.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-30">(accessed on 30 December 2024)</date-in-citation></element-citation></ref><ref id="B167-pharmaceutics-17-00256"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Swofford</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Santiago</surname><given-names>B.G.</given-names></name></person-group><article-title>In Vitro Permeation Test (IVPT) for Pharmacokinetic Assessment of Topical Dermatological Formulations</article-title><source>Curr. Protoc. Pharmacol.</source><year>2020</year><volume>91</volume><fpage>e79</fpage><pub-id pub-id-type="doi">10.1002/cpph.79</pub-id><pub-id pub-id-type="pmid">32991075</pub-id></element-citation></ref><ref id="B168-pharmaceutics-17-00256"><label>168.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. Food and Drug Administration</collab></person-group><article-title>Draft Guidance on Clascoterone. Guidance Index</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213433.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213433.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-30">(accessed on 30 December 2024)</date-in-citation></element-citation></ref><ref id="B169-pharmaceutics-17-00256"><label>169.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. Food and Drug Administration</collab></person-group><article-title>Draft Guidance on Clindamycin Phosphate. Guidance Index</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clindamycin_Phosphate_crm_50680_RC03-12.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/psg/Clindamycin_Phosphate_crm_50680_RC03-12.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-30">(accessed on 30 December 2024)</date-in-citation></element-citation></ref><ref id="B170-pharmaceutics-17-00256"><label>170.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. Food and Drug Administration</collab></person-group><article-title>Draft Guidance on Halobetasol Propionate. Guidance Index</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/psg/Halobetasol%20propionate_topical%20cream_NDA%2019967_RC04-16.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/psg/Halobetasol%20propionate_topical%20cream_NDA%2019967_RC04-16.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-30">(accessed on 30 December 2024)</date-in-citation></element-citation></ref><ref id="B171-pharmaceutics-17-00256"><label>171.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. Food and Drug Administration</collab></person-group><article-title>Draft Guidance on Tazarotene. Guidance Index</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021184-Cre-0.1P.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021184-Cre-0.1P.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-30">(accessed on 30 December 2024)</date-in-citation></element-citation></ref><ref id="B172-pharmaceutics-17-00256"><label>172.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. Food and Drug Administration</collab></person-group><article-title>In Vitro Permeation Test Studies for Topical Drug Prodcuts Submitted in ANDAs. Guidance Index</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/in-vitro-permeation-test-studies-topical-drug-products-submitted-andas" ext-link-type="uri">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/in-vitro-permeation-test-studies-topical-drug-products-submitted-andas</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-30">(accessed on 30 December 2024)</date-in-citation></element-citation></ref><ref id="B173-pharmaceutics-17-00256"><label>173.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Yue</surname><given-names>W.</given-names></name><name name-style="western"><surname>Megan Kelchen</surname><given-names>L.X.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Raney</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name></person-group><article-title>Impact of fatty acids on in vitro performance of clindamycin phosphate vaginal creams</article-title><source>Proceedings of the Controlled Release Society Annual Meeting and Exposition #CRS2023</source><conf-loc>Las Vegas, NV, USA</conf-loc><conf-date>24&#8211;28 July 2023</conf-date></element-citation></ref><ref id="B174-pharmaceutics-17-00256"><label>174.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Megan Kelchen</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Raney</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name></person-group><article-title>Impact of material attributes on in vitro performance of clindamycin phosphate vaginal creams</article-title><source>Proceedings of the PHARMSCI 360, American Association of Pharmaceutical Scientists Annual Meeting and Exposition</source><conf-loc>Boston, MA, USA</conf-loc><conf-date>16&#8211;19 October 2022</conf-date></element-citation></ref><ref id="B175-pharmaceutics-17-00256"><label>175.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>U.S. Food and Drug Administration</collab></person-group><article-title>FY 2023 GDUFA Science and Research Report</article-title><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/generic-drugs/fy-2023-gdufa-science-and-research-report" ext-link-type="uri">https://www.fda.gov/drugs/generic-drugs/fy-2023-gdufa-science-and-research-report</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-30">(accessed on 30 December 2024)</date-in-citation></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00256-f001" orientation="portrait"><label>Figure 1</label><caption><p>Main permeation barriers of representative mucosal administration routes. (<bold>A</bold>) cornea; (<bold>B</bold>) nasal mucosa (respiratory region); (<bold>C</bold>) rectal mucosa; (<bold>D</bold>) vaginal mucosa.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-00256-g001.jpg"/></fig><fig position="float" id="pharmaceutics-17-00256-f002" orientation="portrait"><label>Figure 2</label><caption><p>Schematic diagram of tissue-based (<bold>A</bold>) vertical diffusion cell (VDC), (<bold>B</bold>) flow-through vertical cell apparatus (FTC), (<bold>C</bold>) vertical Ussing chamber apparatus and (<bold>D</bold>) transwell system.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-00256-g002.jpg"/></fig><table-wrap position="float" id="pharmaceutics-17-00256-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-00256-t001_Table 1</object-id><label>Table 1</label><caption><p>Physiological environment of different mucosa.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mucosa</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Surface Area</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Thickness</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">pH of the Fluid</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Volume of the Fluid</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Corneal</td><td align="center" valign="middle" rowspan="1" colspan="1">1.04 cm<sup>2</sup> [<xref rid="B5-pharmaceutics-17-00256" ref-type="bibr">5</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">520 &#956;m [<xref rid="B6-pharmaceutics-17-00256" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">~7.4</td><td align="center" valign="middle" rowspan="1" colspan="1">7&#8211;30 &#956;L [<xref rid="B7-pharmaceutics-17-00256" ref-type="bibr">7</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nasal</td><td align="center" valign="middle" rowspan="1" colspan="1">130 cm<sup>2</sup> (respiratory) [<xref rid="B8-pharmaceutics-17-00256" ref-type="bibr">8</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3&#8211;5 mm (respiratory) [<xref rid="B9-pharmaceutics-17-00256" ref-type="bibr">9</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">5&#8211;6.5</td><td align="center" valign="middle" rowspan="1" colspan="1">75&#8211;135 &#956;L [<xref rid="B10-pharmaceutics-17-00256" ref-type="bibr">10</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rectal</td><td align="center" valign="middle" rowspan="1" colspan="1">200&#8211;400 cm<sup>2</sup> [<xref rid="B11-pharmaceutics-17-00256" ref-type="bibr">11</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">100 &#181;m [<xref rid="B12-pharmaceutics-17-00256" ref-type="bibr">12</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">7.2&#8211;7.4 [<xref rid="B13-pharmaceutics-17-00256" ref-type="bibr">13</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">1&#8211;3 mL [<xref rid="B11-pharmaceutics-17-00256" ref-type="bibr">11</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaginal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">360 cm<sup>2</sup> [<xref rid="B14-pharmaceutics-17-00256" ref-type="bibr">14</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150&#8211;200 &#956;m [<xref rid="B15-pharmaceutics-17-00256" ref-type="bibr">15</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.5&#8211;4.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.51 mL [<xref rid="B16-pharmaceutics-17-00256" ref-type="bibr">16</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00256-t002" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-00256-t002_Table 2</object-id><label>Table 2</label><caption><p>The receptor media used in transmucosal IVPT studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mucosa</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Simulated Fluids in Receptor Cell</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Components of Simulated Fluids in Receptor Cell</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">pH</th></tr></thead><tbody><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Corneal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glutathione bicarbonate Ringer (GBR) buffer [<xref rid="B62-pharmaceutics-17-00256" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceutics-17-00256" ref-type="bibr">63</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NaCl (110 mM), KCl (2 mM), K<sub>2</sub>HPO<sub>4</sub> (1 mM), MgCl<sub>2</sub> (0.6 mM), calcium gluconate (1.4 mM), glucose (5 mM), reduced glutathione (0.3 mM), sodium gluconate (15 mM), and NaHCO<sub>3</sub> (28.5 mM), CO<sub>2</sub> (5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.85</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Balanced salt solution (BSS) buffer solution with 10 mM HEPES [<xref rid="B64-pharmaceutics-17-00256" ref-type="bibr">64</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NaCl 0.64%, KCl 0.075%, CaCl<sub>2</sub>&#183;2H<sub>2</sub>O 0.048%, MgCl<sub>2</sub>6&#183;H<sub>2</sub>O 0.03%, C<sub>2</sub>H<sub>3</sub>NaO<sub>2</sub>&#183;3H<sub>2</sub>O 0.39%, C<sub>6</sub>H<sub>5</sub>Na<sub>3</sub>O<sub>7</sub>&#183;2H<sub>2</sub>O) 0.17%, NaOH and/or HCl to adjust pH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBS [<xref rid="B65-pharmaceutics-17-00256" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceutics-17-00256" ref-type="bibr">66</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">phosphate buffer saline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBS [<xref rid="B67-pharmaceutics-17-00256" ref-type="bibr">67</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">phosphate buffer saline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EBS buffer solution [<xref rid="B68-pharmaceutics-17-00256" ref-type="bibr">68</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Earl&#8217;s balanced salts (EBS)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BSS buffer [<xref rid="B69-pharmaceutics-17-00256" ref-type="bibr">69</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NaCl 0.64%, KCl 0.075%, CaCl<sub>2</sub>&#183;2H<sub>2</sub>O 0.048%, MgCl<sub>2</sub>6&#183;H<sub>2</sub>O 0.03%, C<sub>2</sub>H<sub>3</sub>NaO<sub>2</sub>&#183;3H<sub>2</sub>O 0.39%, C<sub>6</sub>H<sub>5</sub>Na<sub>3</sub>O<sub>7</sub>&#183;2H<sub>2</sub>O) 0.17%, NaOH and/or HCl to adjust pH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.4</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Nasal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transport medium (TM) [<xref rid="B70-pharmaceutics-17-00256" ref-type="bibr">70</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NaCl (136.89 mM), KCl (5.36 mM), Na<sub>2</sub>HPO<sub>4</sub> (0.34 mM), KH<sub>2</sub>PO<sub>4</sub> (0.44 mM), MgSO<sub>4</sub>&#183;7H<sub>2</sub>O (0.41 mM), glucose (19.45 mM), CaCl<sub>2</sub> (1.26 mM), MgCl<sub>2</sub>&#183;6H<sub>2</sub>O (0.49 mM), NaHCO<sub>3</sub> (4.17 mM), and HEPES (10.00 mM).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kreb&#8217;s bicarbonate Ringer&#8217;s solution (KBR) [<xref rid="B71-pharmaceutics-17-00256" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceutics-17-00256" ref-type="bibr">72</xref>,<xref rid="B73-pharmaceutics-17-00256" ref-type="bibr">73</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CaCl<sub>2</sub> (1.25 mM), KCl (4.7 mM), KH<sub>2</sub>PO<sub>4</sub> (0.6 mM), MgSO<sub>4</sub>&#183;7H<sub>2</sub>O (1.2 mM), NaCl (108 mM), NaHCO<sub>3</sub> (16 mM), Na<sub>2</sub>HPO<sub>4</sub> (1.8 mM), d-glucose (11.5 mM), fumarate (5.4 mM), glutamate (4.9 mM) and pyruvate (4.9 mM)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Simulated nasal electrolyte solution (SNES) [<xref rid="B74-pharmaceutics-17-00256" ref-type="bibr">74</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.45 mg/mL NaCl, 1.29 mg/mL KCl and 0.32 mg/mL CaCl<sub>2</sub>&#183;2H<sub>2</sub>O</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBS with 5% DMSO (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) [<xref rid="B75-pharmaceutics-17-00256" ref-type="bibr">75</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">phosphate buffer saline added with 5% DMSO (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.4</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Rectal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1&#215; PBS [<xref rid="B76-pharmaceutics-17-00256" ref-type="bibr">76</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">phosphate buffer saline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBS [<xref rid="B77-pharmaceutics-17-00256" ref-type="bibr">77</xref>,<xref rid="B78-pharmaceutics-17-00256" ref-type="bibr">78</xref>,<xref rid="B79-pharmaceutics-17-00256" ref-type="bibr">79</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">phosphate buffer saline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phosphate buffer solution [<xref rid="B80-pharmaceutics-17-00256" ref-type="bibr">80</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50&#8201;mL phosphate buffer solution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBSS with poloxamer 407 [<xref rid="B81-pharmaceutics-17-00256" ref-type="bibr">81</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hank&#8217;s balanced salt solution (HBSS), added with 0.2% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) poloxamer 407</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saline [<xref rid="B82-pharmaceutics-17-00256" ref-type="bibr">82</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9% <italic toggle="yes">w</italic>/<italic toggle="yes">v</italic> NaCl</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Vaginal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBS [<xref rid="B47-pharmaceutics-17-00256" ref-type="bibr">47</xref>,<xref rid="B83-pharmaceutics-17-00256" ref-type="bibr">83</xref>,<xref rid="B84-pharmaceutics-17-00256" ref-type="bibr">84</xref>,<xref rid="B85-pharmaceutics-17-00256" ref-type="bibr">85</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">phosphate buffer saline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBSS with poloxamer 407 [<xref rid="B81-pharmaceutics-17-00256" ref-type="bibr">81</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hank&#8217;s balanced salt solution (HBSS), added with 0.2% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) poloxamer 407</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ringer buffer [<xref rid="B86-pharmaceutics-17-00256" ref-type="bibr">86</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.5 mL, oxygenated Ringer buffer at pH&#8201;7.4 containing 10 mM glucose, 0.3 g/L L-glutamine, and 2% albumin (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Simulated vaginal fluid [<xref rid="B87-pharmaceutics-17-00256" ref-type="bibr">87</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NaCl (3.51 g/L), KOH (1.4 g/L), Ca(OH)<sub>2</sub> (0.222 g/L), acetic acid (1 g/L), lactic acid (2 g/L), glycerol (0.16 g/L), urea (0.4 g/L), and glucose (5 g/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2</td></tr></tbody></table><table-wrap-foot><fn><p>N/A: no information provided from the literature.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-00256-t003" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-00256-t003_Table 3</object-id><label>Table 3</label><caption><p>Tissue models commonly used in transmucosal IVPT studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mucosa</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Corneal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Goat cornea [<xref rid="B91-pharmaceutics-17-00256" ref-type="bibr">91</xref>], rabbit cornea [<xref rid="B66-pharmaceutics-17-00256" ref-type="bibr">66</xref>,<xref rid="B92-pharmaceutics-17-00256" ref-type="bibr">92</xref>], porcine cornea [<xref rid="B93-pharmaceutics-17-00256" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nasal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human biopsies from posterior part of inferior turbinate of normal patients [<xref rid="B94-pharmaceutics-17-00256" ref-type="bibr">94</xref>], bovine nasal mucosa [<xref rid="B68-pharmaceutics-17-00256" ref-type="bibr">68</xref>,<xref rid="B95-pharmaceutics-17-00256" ref-type="bibr">95</xref>,<xref rid="B96-pharmaceutics-17-00256" ref-type="bibr">96</xref>,<xref rid="B97-pharmaceutics-17-00256" ref-type="bibr">97</xref>], porcine respiratory mucosa [<xref rid="B98-pharmaceutics-17-00256" ref-type="bibr">98</xref>,<xref rid="B99-pharmaceutics-17-00256" ref-type="bibr">99</xref>], rodent nasal mucosa, ovine nasal mucosa [<xref rid="B100-pharmaceutics-17-00256" ref-type="bibr">100</xref>,<xref rid="B101-pharmaceutics-17-00256" ref-type="bibr">101</xref>,<xref rid="B102-pharmaceutics-17-00256" ref-type="bibr">102</xref>], rabbit nasal mucosa [<xref rid="B101-pharmaceutics-17-00256" ref-type="bibr">101</xref>,<xref rid="B103-pharmaceutics-17-00256" ref-type="bibr">103</xref>,<xref rid="B104-pharmaceutics-17-00256" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rectal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cattle and rat rectum [<xref rid="B80-pharmaceutics-17-00256" ref-type="bibr">80</xref>,<xref rid="B105-pharmaceutics-17-00256" ref-type="bibr">105</xref>], porcine rectum [<xref rid="B76-pharmaceutics-17-00256" ref-type="bibr">76</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaginal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Porcine vaginal tissue [<xref rid="B83-pharmaceutics-17-00256" ref-type="bibr">83</xref>], bovine vaginal tissue [<xref rid="B86-pharmaceutics-17-00256" ref-type="bibr">86</xref>], sheep vaginal tissue [<xref rid="B106-pharmaceutics-17-00256" ref-type="bibr">106</xref>,<xref rid="B107-pharmaceutics-17-00256" ref-type="bibr">107</xref>,<xref rid="B108-pharmaceutics-17-00256" ref-type="bibr">108</xref>], human cervical and vaginal tissue [<xref rid="B47-pharmaceutics-17-00256" ref-type="bibr">47</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00256-t004" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-00256-t004_Table 4</object-id><label>Table 4</label><caption><p>Representative cell models reported for transmucosal IVPT using a transwell.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mucosa</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Source</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ophthalmic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HCE-S [<xref rid="B119-pharmaceutics-17-00256" ref-type="bibr">119</xref>,<xref rid="B120-pharmaceutics-17-00256" ref-type="bibr">120</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Corneal epithelial (spontaneous)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SV 40 HCE-T [<xref rid="B120-pharmaceutics-17-00256" ref-type="bibr">120</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Simian virus 40 immortalized human corneal epithelial cells</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human tet HPV16-E6/E7-transduced HCE [<xref rid="B121-pharmaceutics-17-00256" ref-type="bibr">121</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetracycline-responsive human papillomavirus (HPV) 16-E6/E7-transduced human corneal epithelial cell clones</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human organotypic cornea equivalent [<xref rid="B122-pharmaceutics-17-00256" ref-type="bibr">122</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immortalized epithelial (CEP-17-CL4) and endothelial (HENC) cells and primary human stromal cells</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nasal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RPMI 2650 [<xref rid="B70-pharmaceutics-17-00256" ref-type="bibr">70</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human nasal epithelial tissues</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rectal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Caco-2 cell lines (human colon carcinoma) [<xref rid="B123-pharmaceutics-17-00256" ref-type="bibr">123</xref>,<xref rid="B124-pharmaceutics-17-00256" ref-type="bibr">124</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human colon carcinoma</td></tr><tr><td rowspan="10" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Vaginal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hECE (primary) [<xref rid="B125-pharmaceutics-17-00256" ref-type="bibr">125</xref>,<xref rid="B126-pharmaceutics-17-00256" ref-type="bibr">126</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human ectocervical epithelial</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HEC-1A (immortalized) [<xref rid="B127-pharmaceutics-17-00256" ref-type="bibr">127</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uterine endometrial adenocarcinoma</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CaSki (immortalized) [<xref rid="B81-pharmaceutics-17-00256" ref-type="bibr">81</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Endocervical carcinoma cells</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C-33A (immortalized) [<xref rid="B128-pharmaceutics-17-00256" ref-type="bibr">128</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cervical cells</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ECEI6-1 (immortalized) [<xref rid="B125-pharmaceutics-17-00256" ref-type="bibr">125</xref>,<xref rid="B126-pharmaceutics-17-00256" ref-type="bibr">126</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ectocervical carcinoma cells</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HT3 (immortalized) [<xref rid="B125-pharmaceutics-17-00256" ref-type="bibr">125</xref>,<xref rid="B126-pharmaceutics-17-00256" ref-type="bibr">126</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cervical carcinoma cells</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ME-180 (immortalized) [<xref rid="B129-pharmaceutics-17-00256" ref-type="bibr">129</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Endocervical cells</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SiHa (immortalized) [<xref rid="B129-pharmaceutics-17-00256" ref-type="bibr">129</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uterine cervix</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EpiVaginal<sup>&#174;</sup> (cell-based tissue model) [<xref rid="B130-pharmaceutics-17-00256" ref-type="bibr">130</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal, human-derived vaginal ectocervical epithelial and dendritic cells</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HVE<sup>&#174;</sup> (cell-based tissue model) [<xref rid="B131-pharmaceutics-17-00256" ref-type="bibr">131</xref>,<xref rid="B132-pharmaceutics-17-00256" ref-type="bibr">132</xref>,<xref rid="B133-pharmaceutics-17-00256" ref-type="bibr">133</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A431 cells derived from a vulval epidermoid carcinoma grown on a polycarbonate filter</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>